

A

Docket No. 53801/IPW/KDBIN THE UNITED STATES PATENT AND TRADEMARK OFFICEASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

July 16, 1998

S I R:

Transmitted herewith for filing are the specification and claims of the patent application of:

Beth Borowsky and Nika Adham for  
Inventor(s)DNA ENCODING A HUMAN Ob RECEPTOR (Ob-Re) AND USES THEREOF  
Title of Invention

Also enclosed are:

☒ 14 sheet(s) of      informal ☒ formal drawings.     Oath or declaration of Applicant(s).     A power of attorney     An assignment of the invention to                                 ☒      A Preliminary Amendment     A verified statement to establish small entity status under 37 C.F.R. \$1.9 and \$1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE		
					SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	41-20	=	21	X	\$11	\$22	=	\$	\$ 462
Independent Claims	3-3	=	0	X	\$41	\$82	=	\$	\$ 0
Multiple Dependent Claims Presented:      Yes      No					\$135	\$270	=	\$	\$ 0
* If the difference in Col. 1 is less than zero, enter "0" in Col. 2					BASIC FEE			\$ 395	\$ 790
					TOTAL FEE			\$	\$1,252

\* If the difference in Col. 1 is less than zero, enter "0" in Col. 2

1c534 U.S. PTO



07/16/98

1c534 U.S. PTO


09/11/98



Letter of Transmittal  
Page 2

- X A check in the amount of \$ 1,252.00 to cover the filing fee.
- \_\_\_\_\_ Please charge Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_.
- X The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125;
- X Filing fees under 37 C.F.R. §1.16.
- X Patent application processing fees under 37 C.F.R. §1.17.
- \_\_\_\_\_ The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).
- X Three copies of this sheet are enclosed.
- \_\_\_\_\_ A certified copy of previously filed foreign application No. \_\_\_\_\_ filed in \_\_\_\_\_ on \_\_\_\_\_ Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. §119.
- X Other (identify) Express Mail Certificate of Mailing bearing Label No. EM 422 020 776 dated July 16, 1998. Sequence Listing on disk (CRF), Statement in Accordance With 37 C.F.R. 1.821(f)

Respectfully submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicant(s)  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Beth Borowsky, et al.  
U.S. Serial No. : Not Yet Known  
Filed : Herewith  
For : DNA ENCODING A HUMAN Ob RECEPTOR (Ob-  
Re) AND USES THEREOF

1185 Avenue of the Americas  
New York, New York 10036  
July 16, 1998

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box: Patent Application

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(e) and submitted in connection with the above-identified application, has the same information as pages 85-98 of the subject application entitled "Sequence Listing."

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Kimberly D. Branch  
c/o Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Beth Borrowski, et al.  
U.S. Serial No. : Not Yet Known  
Filed : Herewith  
For : DNA ENCODING A HUMAN Ob RECEPTOR (Ob-Re)  
AND USES THEREOF

1185 Avenue of the Americas  
New York, New York 10036  
July 16, 1998

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box: Patent Application

Sir:

PRELIMINARY AMENDMENT

Please amend the subject application as follows.

In the Claims:

Please cancel claims 10-12, 49-70, 72-149 and 151-207 without prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.

REMARKS

Claims 1-207 were pending in the subject application. By this Amendment applicants have canceled claims 10-12, 49-70, 72-149 and 151-207 without prejudice. Accordingly, claims 1-9, 13-48, 71, and 150 are currently pending.

Beth Borowsky, et al.  
Serial No.: Not Yet Known  
Filed: Herewith  
Page 2

If a telephone interview would be of assistance in advancing the prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided.

No fee, other than the enclosed fee of \$1,252.00 for filing this application, is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully Submitted,



---

John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

To all whom it may concern:

Be it known that

Beth Borowsky and Nika Adham

have invented certain new and useful improvements in

DNA ENCODING A HUMAN Ob RECEPTOR (Ob-Re) AND USES THEREOF

of which the following is a full, clear and exact description.

DNA ENCODING A HUMAN Ob RECEPTOR (Ob-Re) AND USES THEREOF5 Background of the Invention

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entirety are hereby incorporated  
10 by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citations for these references may be found at the end of this application, preceding the sequence listing and the claims.

15 The *ob* gene has recently been cloned and shown to encode a 146 amino acid protein called *leptin* which is secreted into the blood exclusively by white fat adipocytes. The leptin receptor has also recently been cloned and shown  
20 to exist as several splice variants. The functional splice variant (Ob-Rb) is present in several tissues including hypothalamus, adipocytes and kidney. The short form splice variant (Ob-Ra) has a more ubiquitous tissue distribution and is more abundant than the functional  
25 splice variant. The role of Ob-Ra is unknown but this splice variant may serve as a leptin transport system in choroid plexus, kidney and perhaps also the lung. A third major splice variant (Ob-Re) has also been described in mice which encodes only the extracellular  
30 domain of the receptor, giving rise to a soluble protein in the circulation which may function there as a leptin binding/buffering system.

Circulating leptin acts as an antiobesity agent by  
35 restraining appetite and altering metabolic processes to burn fat. The hypothalamus appears to be the major target tissue for the hormone since leptin receptors are present there and intracerebroventricular injection of leptin leads to a reduction of food intake. Recent  
40 evidence suggests that at least part of the reduction in food intake produced by leptin may be due to a decrease

in central neuropeptide Y. It is unclear whether the changes in metabolism produced by leptin are mediated by actions only on the brain or also involve direct effects upon peripheral tissues. Although the mechanism of action has not been fully elucidated, leptin may be the long sought after satiety factor released from the periphery (i.e. the adipocytes) to regulate long-term body weight. As body weight and fat mass increase, more leptin is secreted which may inhibit appetite and increase metabolism to bring the fat mass back to a certain set point. The incapacity to express a functional leptin is the cause of obesity in the ob/ob mouse. Defects in the functional leptin receptor such as those found in the db/db mouse and the fa/fa rat are responsible for the obesity observed in these animal models.

The observation that obese animals and man, although having high plasma leptin levels remain overweight, may suggest the development of 'resistance' to the actions of leptin. This may occur at the level of the brain and be due to saturation of the leptin uptake system. Alternatively, 'resistance' may be due to the presence of a circulating binding protein which by buffering leptin might reduce its actions.

The single gene defects of rodents described above may play only a minor role in human obesity. However, leptin is present in man, thus, pharmacological stimulation of the leptin pathway has the potential to reduce body weight in man by inhibiting food intake and diminishing the size of the body fat stores. Such therapeutic interventions could be achieved either by enhancing leptin release from the adipocytes, preventing the breakdown or clearance of leptin, preventing interaction of leptin binding to the soluble binding protein, by administration of leptin mimics or by stimulating events



downstream of the leptin receptor. On the other hand, pharmacological inhibition of leptin action or production may have the potential to increase food intake and body weight in man. Evidence to support this comes from the ob/ob and db/db mouse and the fa/fa rat in which the actions of leptin are not apparent. These animals are obese and hyperphagic.

Applicants now report the isolation of a novel human Ob-Re receptor, referred to herein as "hOb-Re" or the "polypeptide." This discovery provides a novel approach to the treatment of eating disorders, both by therapeutic administration of the soluble human Ob-Re receptor to subjects suffering from such disorders, and through the use of heterologous expression systems to develop high-affinity compounds that could serve as therapeutic agents for such disorders.

Summary of the Invention

This invention is directed to an isolated nucleic acid which encodes a polypeptide comprising the amino acid sequence shown in Figure 5 (Seq. I.D. No. 10) or a polypeptide having a sequence which varies therefrom by no more than 15 amino acids, such amino acid variations not involving amino acid positions 799-804 and not changing the functional properties of the polypeptide.

This invention is additionally directed to a nucleic acid which comprises the nucleic acid of above linked to a nucleic acid encoding a polypeptide corresponding to an artificial transmembrane region of a receptor which is not an Ob receptor.

This invention is additionally directed to a nucleic acid which comprises the nucleic acid of above linked to nucleic acid encoding a polypeptide corresponding to an artificial intracellular domain of a receptor which is not an Ob receptor.

This invention is additionally directed to purified polypeptides encoded by the nucleic acid of this invention.

This invention is additionally directed to vectors comprising the nucleic acid of this invention.

This invention is additionally directed to cells comprising the vector of this invention.

This invention is additionally directed to a membrane preparation isolated from the cell of this invention.

This invention is additionally directed to a nucleic acid probe comprising at least 15 nucleotides, which probe has

a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence from nucleotide number 2395 through nucleotide number 2412 of Figure 4 (Seq. I.D. No. 9) or (b) a reverse complement thereof.

5

This invention is additionally directed to an antisense oligonucleotide having a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence from nucleotide number 2395 through nucleotide number 2412 of Figure 4 (Seq. I.D. No. 9) or (b) a reverse complement thereof.

10

This invention is additionally directed to an antibody capable of specifically binding to the polypeptide containing at least a unique sequence corresponding to a sequence present within the amino acid sequence from amino acid number 799 through amino acid number 804 of Figure 5 (Seq. I.D. No. 10).

15

This invention is additionally directed to a pharmaceutical composition comprising an amount of the oligonucleotide effective to reduce expression of a polypeptide and a pharmaceutically acceptable carrier.

20

This invention is additionally directed to a pharmaceutical composition which comprises an amount of the antibody effective to block binding of a ligand to the polypeptide and a pharmaceutically acceptable carrier.

25

This invention is additionally directed to a transgenic nonhuman mammal expressing a nucleic acid of this invention.

30

This invention is directed to a process for identifying a chemical compound which specifically binds to a polypeptide of this invention, which comprises contacting

35

the polypeptide with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the polypeptide.

5 This invention is additionally directed to a process involving competitive binding for identifying a chemical compound which specifically binds to a polypeptide of this invention which comprises separately contacting the polypeptide, with both the chemical compound and a second  
10 chemical compound known to bind to the polypeptide, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the polypeptide, a decrease in the binding of the second  
15 chemical compound to the polypeptide in the presence of the chemical compound indicating that the chemical compound binds to the polypeptide.

This invention is additionally directed to a process for  
20 identifying a chemical compound which specifically binds to a polypeptide encoded by a nucleic acid of this invention, which comprises contacting cells containing DNA encoding and expressing on the cell surface the polypeptide, with the compound under conditions suitable  
25 for binding, and detecting specific binding of the chemical compound to the polypeptide.

This invention is directed to a process for identifying a chemical compound which specifically binds to a  
30 polypeptide encoded by a nucleic acid of this invention, which comprises contacting a membrane fraction from a cell extract of cells containing DNA encoding and expressing on their cell surface the polypeptide, with the compound under conditions suitable for binding, and  
35 detecting specific binding of the chemical compound to the polypeptide.

This invention is directed to a process involving competitive binding for identifying a chemical compound which specifically binds to a polypeptide encoded by a nucleic acid of this invention, which comprises  
5 separately contacting cells expressing on their cell surface the polypeptide, with both the chemical compound and a second chemical compound known to bind to the polypeptide, and with only the second chemical compound, under conditions suitable for binding of both compounds,  
10 and detecting specific binding of the chemical compound to the polypeptide, a decrease in the binding of the second chemical compound to the polypeptide in the presence of the chemical compound indicating that the chemical compound binds to the polypeptide.

This invention is directed to a process involving competitive binding for identifying a chemical compound which specifically binds to a polypeptide encoded by a nucleic acid of this invention, which comprises  
20 separately contacting a membrane fraction from a cell extract of cells expressing on their cell surface the polypeptide, with both the chemical compound and a second chemical compound known to bind to the polypeptide, and with only the second chemical compound, under conditions  
25 suitable for binding of both compounds, and detecting specific binding of the chemical compound to the polypeptide, a decrease in the binding of the second chemical compound to the polypeptide in the presence of the chemical compound indicating that the chemical  
30 compound binds to the polypeptide.

This invention is directed to a method of screening a plurality of chemical compounds not known to bind to a polypeptide encoded by a nucleic acid of this invention  
35 to identify a compound which specifically binds to the polypeptide, which comprises:

- 5 (a) contacting cells transfected with and expressing DNA encoding the polypeptide with a compound known to bind specifically to the polypeptide;
- 10 (b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically to the polypeptide, under conditions permitting binding of compounds known to bind the polypeptide;
- 15 (c) determining whether the binding of the compound known to bind to the polypeptide is reduced in the presence of the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so
- 20 (d) separately determining the binding to the polypeptide of each compound included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the polypeptide.

25 This invention is directed to a method of screening a plurality of chemical compounds not known to bind to a polypeptide of this invention to identify a compound which specifically binds to the polypeptide, which comprises:

- 30 (a) preparing a cell extract or cell supernatant from cells transfected with and expressing DNA encoding the polypeptide and contacting the cell extract or cell supernatant with a
- 35 compound known to bind specifically to the polypeptide;

- 5 (b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically to the polypeptide, under conditions permitting binding of compounds known to bind the polypeptide;
- 10 (c) determining whether the binding of the compound known to bind to the polypeptide is reduced in the presence of the compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so
- 15 (d) separately determining the binding to the polypeptide of each compound included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the polypeptide.

20 This invention is directed to a process for determining whether a chemical compound is an Ob receptor agonist which comprises contacting cells transfected with and expressing DNA of this invention with the compound under conditions permitting the activation of the Ob receptor, and detecting an increase in Ob receptor activity, so as

25 to thereby determine whether the compound is an Ob receptor agonist.

30 This invention is directed to a process for determining whether a chemical compound is an Ob receptor agonist which comprises preparing a cell extract from cells transfected with and expressing DNA of this invention, isolating a membrane fraction from the cell extract, contacting the membrane fraction with the compound under conditions permitting the activation of the Ob receptor,

35 and detecting an increase in Ob receptor activity, so as to thereby determine whether the compound is an Ob

receptor agonist.

5 This invention is directed to a process for determining whether a chemical compound is an Ob receptor antagonist which comprises contacting cells transfected with and expressing DNA of this invention with the compound in the presence of a known Ob receptor agonist, under conditions permitting the activation of an Ob receptor, and detecting a decrease in Ob receptor activity, so as to  
10 thereby determine whether the compound is an Ob receptor antagonist.

15 This invention is directed to a process for determining whether a chemical compound is an Ob receptor antagonist which comprises preparing a cell extract from cells transfected with and expressing DNA of this invention, isolating a membrane fraction from the cell extract, contacting the membrane fraction with the ligand in the presence of a known Ob receptor agonist, under conditions  
20 permitting the activation of the Ob receptor, and detecting a decrease in Ob receptor activity, so as to thereby determine whether the compound is an Ob receptor antagonist.

25 This invention is directed to a pharmaceutical composition comprising an effective amount of a polypeptide of this invention and a pharmaceutically acceptable carrier.

30 This invention is directed to a method for determining whether a compound modulates leptin activity which comprises:

35 (a) administering to an animal a polypeptide of this invention and measuring the amount of food intake, metabolic, or body weight changes in



the animal;

5 (b) administering to a second animal both the polypeptide and the compound, and measuring the amount of food intake, metabolic, or body weight changes in the second animal; and

10 (c) determining whether the amount of food intake, metabolic, or body weight change is altered in the presence of the compound relative to the amount of food intake, metabolic, or body weight change in the absence of the compound, so as to thereby determine whether the compound modulates leptin activity.

15 This invention is directed to a method of screening a plurality of compounds to identify a compound which modulates leptin activity which comprises:

20 (a) administering to an animal a polypeptide of this invention and measuring the amount of food intake, metabolic, or body weight changes in the animal;

25 (b) administering to a second animal the polypeptide and at least one compound of the plurality of compounds and measuring the amount of food intake, metabolic, or body weight changes in the animal;

30 (c) determining whether the amount of food intake, metabolic, or body weight change is altered in the presence of at least one compound of the plurality relative to the amount of food intake, metabolic, or body weight change in the  
35 absence of at least one compound of the plurality, and if so;

- (d) separately determining whether each compound modulates leptin activity according to the method of this invention, so as to thereby identify a compound which modulates leptin activity.

5

This invention is directed to a method of treating an abnormality in a subject, wherein the abnormality is alleviated by modulating the activity of leptin in the subject, which comprises administering to a subject an amount of the pharmaceutical composition of this invention effective to modulate the activity of leptin in the subject, thereby treating the abnormality in the subject.

10

15

This invention is directed to a method of modulating feeding behavior or metabolism of a subject which comprises administering to the subject an amount of a polypeptide of this invention effective to modulate the feeding behavior or metabolism of the subject so as to thereby modulate feeding behavior or metabolism of the subject.

20

25

This invention is directed to a method of modulating feeding behavior or metabolism of a subject which comprises administering a polypeptide of this invention and a compound which binds to the Y5 receptor, the amount of such polypeptide and compound being effective to modulate the feeding behavior or metabolism of the subject.

30

This invention is directed to a method of modulating feeding behavior or metabolism in a subject which comprises administering to the subject an amount of a compound which binds to a polypeptide of this invention effective to alter the activity of leptin in the subject, so as to thereby modulate feeding behavior or metabolism

35

of the subject.

5 This invention is directed to a method of modulating feeding behavior or metabolism of a subject which comprises administering a compound which binds to a polypeptide of this invention and a second compound which binds to the Y5 receptor, the amount of the first compound and the second compound being effective to modulate the feeding behavior or metabolism of the  
10 subject.

15 This invention is directed to a method of detecting expression of a polypeptide of this invention by detecting the presence of mRNA coding for the polypeptide which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with the nucleic acid probe of this invention under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of the polypeptide  
20 by the cell.

25 This invention is directed to a method of detecting the presence of a polypeptide which comprises contacting the cell or cell supernatant with the antibody of this invention under conditions permitting binding of the antibody to the polypeptide, detecting the presence of the antibody bound to the cell or cell supernatant, and thereby detecting the presence of a polypeptide.

30 This invention is directed to a method of determining the physiological effects of varying levels of activity of polypeptides which comprises producing a transgenic nonhuman mammal of this invention whose levels of polypeptide activity are varied by use of an inducible  
35 promoter which regulates polypeptide expression.

This invention is directed to a method of determining the

0316676-1774652

physiological effects of varying levels of activity of polypeptides which comprises producing a panel of transgenic nonhuman mammals of this invention each expressing a different amount of polypeptide.

5

This invention is directed to a method for diagnosing a predisposition to a disorder associated with the activity of a specific polypeptide allele which comprises:

10

(a) obtaining DNA of subjects suffering from the disorder;

15

(b) performing a restriction digest of the DNA with a panel of restriction enzymes;

20

(c) electrophoretically separating the resulting DNA fragments on a sizing gel;

25

(d) contacting the resulting gel with a nucleic acid probe capable of specifically hybridizing with a unique sequence included within the sequence of a nucleic acid molecule encoding a polypeptide and labeled with a detectable marker;

30

(e) detecting labeled bands which have hybridized to the nucleic acid of this invention labeled with a detectable marker to create a unique band pattern specific to the DNA of subjects suffering from the disorder;

35

(f) preparing DNA obtained for diagnosis by steps a-e; and  
(g) comparing the unique band pattern specific to the DNA of subjects suffering from the disorder from step e and the DNA obtained for diagnosis

from step f to determine whether the patterns are the same or different and to diagnose thereby predisposition to the disorder if the patterns are the same.

5

This invention is directed to a method of preparing the purified polypeptide of this invention which comprises:

10

- (a) inducing cells to express the polypeptide;
- (b) recovering the polypeptide from the induced cells; and
- (c) purifying the polypeptide so recovered.

15

This invention is directed to a method of preparing the purified polypeptide of this invention which comprises:

20

- (a) inserting nucleic acid encoding the polypeptide in a suitable vector;
- (b) introducing the resulting vector in a suitable host cell;

25

- (c) placing the resulting cell in suitable condition permitting the production of the isolated polypeptide;

30

- (d) recovering the polypeptide produced by the resulting cell; and
- (e) purifying the polypeptide so recovered.

35

Brief Description of the Figures

- Figure 1** Schematic of the likely genomic structure for the 3' end of the mouse Ob-R gene based on previous findings. Boxes represent exons, horizontal lines represent introns, and diagonal lines indicate exon splicing. The first two exons shown represent the two 3'-most exons that are common to all splice variants. The fourth exon shown represents an exon common to all splice variants other than Ob-Re. The remaining exons are specific for individual splice variants. Primers in exons believed to be immediately upstream (BB130) and downstream (BB131) of the mOb-Re-specific exon are shown.
- Figures 2a and 2b** Schematic illustrating the two potential structures of the 3' end of the mouse Ob-R gene based on current findings. Boxes represent exons, horizontal lines represent introns, and diagonal lines indicate exon splicing. **Figure 2a:** The mOb-Re-specific sequence may be encoded by an exon that is contiguous to the 3'-most common exon. **Figure 2b:** The mOb-Re-specific sequence may be encoded by an unspliced intron. The asterisk represents the stop codon in mOb-Re.
- Figures 3a and 3b** **Figure 3a:** Nucleotide sequence and deduced amino acid sequence (Seq. I.D. Nos.: 1 and 2, respectively) of mouse genomic DNA, and nucleotide and deduced amino acid sequence (Seq. I.D. Nos.: 3 and 4, respectively) of human genomic DNA across the intron-exon border of the 3' most common exon. Residues in normal type represent the 3' end of the exon, and residues in bold represent the 5' end of the intron. The mouse sequence in bold is identical to the published mOb-Re sequence. The human sequence in bold is the hOb-Re-specific sequence. **Figure 3b:** Comparison of the mouse Ob-Re-specific nucleotide and amino acid sequence (Seq. I.D. Nos.: 5 and 6, respectively) with the human Ob-Re-

specific nucleotide and amino acid sequences (Seq. I.D. Nos.: 7 and 8, respectively). Underlined residues are conserved across the species.

5 Figures 4a-4b Nucleotide coding sequence of the human Ob-Re receptor (Seq. I.D. No. 9), including stop codon (TAG).

10 Figures 5a-5b Deduced amino acid sequence of the human Ob-Re receptor (Seq. I.D. No. 10) encoded by the human nucleotide sequence shown in Figure 4.

Figures 6a and 6b Schematics illustrating the two potential structures of the 3' end of the human Ob-R gene based on current findings. Boxes represent exons, horizontal lines represent introns, and diagonal lines indicate exon splicing. Figure 6a: The hOb-Re-specific sequence may be encoded by an exon that is contiguous to the 3'-most common exon. Figure 6b: The hOb-Re-specific sequence may be encoded by an unspliced intron. The asterisk represents the stop codon in hOb-Re.

15  
20

Figures 7a-7d Optimization of binding of [<sup>125</sup>I]leptin to Mock- (vector only) and hOb-Re-transfected Cos-7 cells. Cos-7 cells were transiently transfected as described under Methods. Following transfection, cells were incubated for the indicated number of days and binding of [<sup>125</sup>I]leptin was measured in the medium (Figure 7a) as well as on the cells (Figure 7c) using SPA beads (see Methods). Binding of [<sup>125</sup>I]leptin in medium (Figure 7b) or on cells (Figure 7d) was determined in the manner using mock (vector only) transfected cells. Results are expressed as cpm bound/well. Experiments were carried out in triplicate.

25  
30  
35

Figure 8 Effect of different growth media on the binding of [<sup>125</sup>I]leptin to hOb-Re receptor.

Cos-7 cells were transfected with hOb-Re as described in the Methods and grown in either optmem or DMEM medium. Binding of [ $^{125}$ I]leptin was evaluated 48 hrs following transfection, using SPA beads as described in the Methods. Results are expressed as % maximum specific binding obtained in the absence of unlabeled leptin. Experiments were carried out in triplicate and results are means  $\pm$  S.E.M.  $IC_{50}$  values indicate the concentration of unlabeled leptin displacing 50% of maximum specific binding. Binding data were analyzed by nonlinear regression analysis.

**Figure 9** Displacement of [ $^{125}$ I]leptin binding by unlabeled leptin on Cos-7 cells transfected with human Ob-Rb. Cos-7 cells were transfected with human Ob-Rb as described in the Methods. Binding of [ $^{125}$ I]leptin was evaluated 48 hours following transfection using SPA beads as described in the Methods. Results are expressed as % maximum specific binding obtained in the absence of unlabeled leptin. Experiments were carried out in triplicate and results are means  $\pm$  S.E.M.  $IC_{50}$  values indicate the concentration of unlabeled leptin displacing 50% of maximum specific binding. Binding data were analyzed by nonlinear regression analysis.

**Figures 10a-10d** Optimization of binding of [ $^{125}$ I]leptin to hOb-Re from transfected SF21 insect cells. hOb-Re was expressed in SF21 insect cells and binding assays were conducted to optimize both the MOI and the time course for binding as described in Methods. MOI of 1-10 and supernatant collected after 48 hours (Figure 10a), 72 hours. (Figure 10b), 96 hours. (Figure 10c) and 120 hrs (Figure 10d) post-infection were evaluated. Results are means  $\pm$  S.E.M. of triplicate determinations expressed as cpm bound/well. "Wt" indicates wild type and "Un" indicates untransfected.



Figures 11a and 11b Affinity of unlabeled leptin for hOb-Re receptor from infected insect SF21 cells. The cells were infected with BO45 viral stock either undiluted (Figure 11a) or diluted 1:2 (Figure 11b). 500 mL of a high titer stock of virus was prepared at an MOI of 0.1 and supernatant was collected 5 days post infection and tested for binding, as described in the Methods. Results are expressed as % maximum specific binding obtained in the absence of unlabeled leptin. Experiments were carried out in triplicate.  $IC_{50}$  values indicate the concentration of unlabeled leptin displacing 50% of maximum specific binding. Binding data were analyzed by nonlinear regression analysis.

Detailed Description of the Invention

Throughout this application, the following standard abbreviations are used to indicate specific nucleotide bases:

C=cytosine	A=adenine
T=thymine	G=guanine

This invention is directed to an isolated nucleic acid which encodes a polypeptide comprising the amino acid sequence shown in Figure 5 (Seq. I.D. No. 10) or a polypeptide having a sequence which varies therefrom by no more than 15 amino acids (preferably no more than 10 amino acids and more preferably no more than 5 amino acids), such amino acid variations not involving amino acid positions 799-804 and not changing the functional properties of the polypeptide. In regard to the foregoing, variations include additions, deletions, substitutions or combinations thereof.

In one embodiment, nucleic acid encodes a polypeptide having the amino acid sequence shown in Figure 5 (Seq. I.D. No. 10).

In another embodiment, the nucleic acid is DNA. In another embodiment, the DNA is cDNA. In another embodiment, the DNA is genomic DNA. In another embodiment, the nucleic acid is RNA. In another embodiment, the nucleic acid is linked to a nucleic acid encoding a flag epitope.

This invention is directed to a nucleic acid which comprises the nucleic acid of this invention linked to a nucleic acid encoding a polypeptide corresponding to an artificial transmembrane region of a receptor which is

not an Ob receptor.

This invention is directed to a nucleic acid which comprises the nucleic acid of this invention linked to nucleic acid encoding a polypeptide corresponding to an artificial intracellular domain of a receptor which is not an Ob receptor.

Heterologous expression systems utilizing appropriate host cells to express the nucleic acid of the subject invention are used to obtain the desired cellular response.

This invention is directed to a purified polypeptide encoded by the nucleic acid of this invention.

The polypeptides described hereinabove may be transfected into cells either transiently or stably using methods well-known in the art, examples of which are disclosed herein. This invention further provides for a compound identified using a polypeptide in a binding assay such as the binding assays described herein.

In another embodiment, the nucleic acid encoding the polypeptide comprises an intron. In still another embodiment, the nucleic acid encoding the polypeptide comprises alternately spliced nucleic acid. The existence and use of alternative exons is possible, whereby the mRNA may encode different amino acids within the region comprising the exon. In addition, single amino acid substitutions may arise via the mechanism of RNA editing such that the amino acid sequence of the expressed polypeptide is different than that encoded by the original gene (Burns et al., 1996; Chu et al., 1996). Such variants may exhibit pharmacologic properties differing from the polypeptide encoded by the original gene. This invention provides a splice variant of the polypeptides disclosed herein. This invention further

provides for alternate translation initiation sites and alternately spliced or edited variants of nucleic acids encoding the polypeptides.

5 This invention provides the above-described isolated nucleic acids, wherein the nucleic acid is DNA. In an embodiment, the DNA is cDNA. In another embodiment, the DNA is genomic DNA. In still another embodiment, the nucleic acid molecule is RNA. Methods for production and  
10 manipulation of nucleic acid molecules are well known in the art

This invention is directed to a vector comprising the nucleic acid of this invention.

15 In one embodiment, the vector is adapted for expression in a bacterial cell which comprises the regulatory elements necessary for expression of the nucleic acid in the bacterial cell operatively linked to the nucleic acid  
20 encoding the polypeptide so as to permit expression thereof.

In another embodiment, the vector is adapted for expression in a yeast cell which comprises the regulatory elements necessary for expression of the nucleic acid in the yeast cell operatively linked to the nucleic acid  
25 encoding the polypeptide so as to permit expression thereof.

30 In another embodiment, the vector is adapted for expression in an insect cell which comprises the regulatory elements necessary for expression of the nucleic acid in the insect cell operatively linked to the nucleic acid encoding the polypeptide so as to permit  
35 expression thereof.

In another embodiment, the vector is a baculovirus

vector.

In another embodiment, the baculovirus vector is designated Bac-B045 (ATCC Accession No. VR-2574).

5

In another embodiment, the vector is adapted for expression in an amphibian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the amphibian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.

10

In another embodiment, the vector is adapted for expression in a mammalian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the mammalian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.

15

This invention is directed to a plasmid vector of this invention.

20

In one embodiment, the plasmid vector is adapted for expression in a mammalian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the mammalian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.

25

In one embodiment, the plasmid vector is designated B0-25 (ATCC Accession No. 209036).

30

In another embodiment, the vector comprises the nucleic acid of this invention.

35

In another embodiment, the vector is adapted for expression in a bacterial cell which comprises the

regulatory elements necessary for expression of the nucleic acid in the bacterial cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.

5

In another embodiment, the vector is adapted for expression in a yeast cell which comprises the regulatory elements necessary for expression of the nucleic acid in the yeast cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.

10

In another embodiment, the vector is adapted for expression in an insect cell which comprises the regulatory elements necessary for expression of the nucleic acid in the insect cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.

15

This invention is directed to a baculovirus vector of this invention.

20

In another embodiment, the vector is adapted for expression in an amphibian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the amphibian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.

25

In another embodiment, the vector is adapted for expression in a mammalian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the mammalian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.

30

35

This invention is directed to a plasmid vector of this

invention.

5 In one embodiment, the plasmid vector of this invention adapted for expression in a mammalian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the mammalian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.

10 This invention further provides nucleic acid which is degenerate with respect to DNA encoding any of the above-described polypeptides. In an embodiment, the nucleic acid comprises a nucleotide sequence which is degenerate with respect to the nucleotide sequence shown in Figure 4 (Seq. I.D. No. 9) or in plasmid BO-25, that is, a nucleotide sequence which is translated into the same amino acid sequence.

20 This invention also encompasses DNAs and cDNAs which encode amino acid sequences which differ from those of the above-described polypeptides, but which should not produce phenotypic changes. Alternatively, this invention also encompasses DNAs, cDNAs, and RNAs which hybridize to the DNA, cDNA, and RNA of the subject invention. Hybridization methods are well known to those of skill in the art.

30 The nucleic acids of the subject invention also include nucleic acid molecules coding for polypeptide analogs, fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues (deletion analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues specified are replaced by other residues and addition analogs where in one or more

amino acid residues is added to a terminal or medial portion of the polypeptides) and which share some or all properties of naturally-occurring forms. These molecules include: the incorporation of codons "preferred" for expression by selected non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA sequences that facilitate construction of readily expressed vectors.

The modified polypeptides described hereinabove may be transfected into cells either transiently or stably using methods well-known in the art, examples of which are disclosed herein. This invention further provides for a compound identified using a polypeptide in a binding assay such as the binding assays described herein.

The nucleic acids described and claimed herein are useful for the information which they provide concerning the amino acid sequence of the polypeptide and as products for the large scale synthesis of the polypeptide by a variety of recombinant techniques. The nucleic acid molecule is useful for generating new cloning and expression vectors, transformed and transfected prokaryotic and eukaryotic host cells, and new and useful methods for cultured growth of such host cells capable of expression of the polypeptide and related products.

Vectors which comprise the isolated nucleic acid molecule described hereinabove also are provided. Suitable vectors comprise, but are not limited to, a plasmid or a virus. These vectors may be transformed into a suitable host cell to form a host cell expression system for the production of a polypeptide having the biological activity of the polypeptide. Suitable host cells include, for example, neuronal cells such as the glial cell line C6, a Xenopus cell such as an oocyte or



melanophore cell, as well as numerous mammalian cells and non-neuronal cells.

5 This invention provides a baculovirus designated Bac-BO45 (ATCC Accession No. VR-2574) which comprises the regulatory elements necessary for expression of DNA in an insect cell operatively linked to DNA encoding the polypeptide so as to permit expression thereof.

10 This baculovirus (Bac-BO45) was deposited on May 15, 1997, with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of  
15 Microorganisms for the Purposes of Patent Procedure and was accorded ATCC Accession No. VR-2574.

This invention provides a plasmid designated BO-25 (ATCC Accession No. 209036) which comprises the regulatory  
20 elements necessary for expression of DNA in a mammalian cell operatively linked to DNA encoding the polypeptide so as to permit expression thereof.

This plasmid (BO-25) was deposited on May 15, 1997, with  
25 the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of  
30 Microorganisms for the Purposes of Patent Procedure and was accorded ATCC Accession No. 209036.

This invention further provides for any vector or plasmid which comprises modified untranslated sequences, which are beneficial for expression in desired host cells or  
35 for use in binding or functional assays. For example, a vector or plasmid with untranslated sequences of varying lengths may express differing amounts of the polypeptide

depending upon the host cell used. In an embodiment, the vector or plasmid comprises the coding sequence of the polypeptide and the regulatory elements necessary for expression in the host cell.

5

This invention provides a cell comprising the above-described plasmid or vector. In an embodiment, the cell is a non-mammalian cell. In a further embodiment, the non-mammalian cell is a *Xenopus* oocyte cell or a *Xenopus* melanophore cell.

10

This invention is directed to a cell comprising the vector of this invention.

15

In one embodiment, the cell is a non-mammalian cell.

In one embodiment, the non-mammalian cell is a *Xenopus* oocyte cell or a *Xenopus* melanophore cell.

20

In another embodiment, the cell is a mammalian cell.

In another embodiment, the mammalian cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell, an LM(tk-) cell or a CHO cell.

25

This invention is directed to a insect cell comprising the vector of this invention.

30

In one embodiment, the insect cell is an Sf9 cell, an Sf21 cell or a HighFive cell.

This invention is directed to a cell comprising the vector of this invention.

35

In one embodiment, the cell is a non-mammalian cell.

In another embodiment, the non-mammalian cell is a

Xenopus oocyte cell or a Xenopus melanophore cell.

In another embodiment, the cell is a mammalian cell.

5 In another embodiment, the mammalian cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell, an LM(tk-) cell or a CHO cell.

10 This invention is directed to an insect cell comprising the vector of this invention.

In one embodiment, the insect cell is an Sf9 cell, an Sf21 cell or a HighFive cell.

15 This invention is directed to a membrane preparation isolated from the cell this invention.

In one embodiment, the membrane preparation is isolated from the cell of this invention.

20 This invention is directed to a nucleic acid probe comprising at least 15 nucleotides, which probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence from nucleotide number 2395 through nucleotide number 2412 of Figure 4  
25 (Seq. I.D. No. 9) or (b) a reverse complement thereof.

In one embodiment, the nucleotides are deoxyribonucleotides.

30 In another embodiment, the nucleotides are ribonucleotides.

35 As used herein, the phrase "specifically hybridizing" means the ability of a nucleic acid molecule to recognize a nucleic acid sequence complementary to its own and to form double-helical segments through hydrogen bonding

between complementary base pairs.

5 Nucleic acid probe technology is well known to those skilled in the art who will readily appreciate that such probes may vary greatly in length and may be labeled with a detectable label, such as a radioisotope or fluorescent dye, to facilitate detection of the probe. DNA probe molecules may be produced by insertion of a DNA molecule which encodes the polypeptide into suitable vectors, such as plasmids or bacteriophages, followed by transforming into suitable bacterial host cells, replication in the transformed bacterial host cells and harvesting of the DNA probes, using methods well known in the art. Alternatively, probes may be generated chemically from  
10 DNA synthesizers.  
15

RNA probes may be generated by inserting the DNA molecule which encodes the polypeptide downstream of a bacteriophage promoter such as T3, T7 or SP6. Large amounts of RNA probe may be produced by incubating the labeled nucleotides with the linearized fragment where it contains an upstream promoter in the presence of the appropriate RNA polymerase.  
20

25 This invention is directed to an antisense oligonucleotide having a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence from nucleotide number 2395 through nucleotide number 2412 of Figure 4 (Seq. I.D. No. 9) or (b) a reverse complement thereof.  
30

In one embodiment, the antisense oligonucleotide is capable of specifically hybridizing to mRNA, so as to prevent translation of mRNA.  
35

In another embodiment, the antisense oligonucleotide is capable of specifically hybridizing to genomic DNA.

In another embodiment, the antisense oligonucleotide comprises chemically modified nucleotides or nucleotide analogues.

5 This invention is directed to an antibody capable of specifically binding to the polypeptide containing at least a unique sequence corresponding to a sequence present within the amino acid sequence from amino acid number 799 through amino acid number 804 of Figure 5  
10 (Seq. I.D. No. 10).

In one embodiment, the antibody is capable of competitively inhibiting the binding of the antibody of claim 56 to the polypeptide to which it specifically binds.  
15

In another embodiment, the antibody is a monoclonal antibody.

20 This invention is directed to a pharmaceutical composition comprising an amount of the oligonucleotide of this invention effective to reduce expression of a polypeptide and a pharmaceutically acceptable carrier.

25 In one embodiment, the oligonucleotide is coupled to a substance which inactivates mRNA.

In one embodiment, the substance which inactivates mRNA is a ribozyme.  
30

In one embodiment, the pharmaceutically acceptable carrier comprises a structure which binds to a receptor on a cell capable of being taken up by the cells after binding to the structure.  
35

In another embodiment, wherein the pharmaceutically acceptable carrier is capable of binding to a receptor

which is specific for a selected cell type.

This invention is directed to a pharmaceutical composition which comprises an amount of the antibody of  
5 this invention effective to block binding of a ligand to the polypeptide and a pharmaceutically acceptable carrier.

This invention provides a pharmaceutical composition  
10 comprising an amount of a compound effective to increase the activity of leptin and a pharmaceutically acceptable carrier. Included in this invention are pharmaceutically acceptable salts and complexes of all of the polypeptides and compounds described herein.

This invention provides the above-described  
15 pharmaceutical composition which comprises an amount of the antibody effective to block binding of a ligand to the above-described polypeptides and a pharmaceutically acceptable carrier.  
20

In the practice of this invention the "pharmaceutically acceptable carrier" is any physiological carrier known to  
25 those of ordinary skill in the art useful in formulating pharmaceutical compositions. Examples include, but are not limited to, phosphate buffered saline, physiological saline, water and emulsions, such as oil/water emulsions.

In one embodiment the pharmaceutical carrier may be a  
30 liquid and the pharmaceutical composition would be in the form of a solution. In another embodiment, the pharmaceutically acceptable carrier is a solid and the composition is in the form of a powder or tablet. In a further embodiment, the pharmaceutical carrier is a gel  
35 and the composition is in the form of a suppository or cream. In a further embodiment the compound may be formulated as a part of a pharmaceutically acceptable

transdermal patch.

A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For

parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by for example, intramuscular, intrathecal, epidural, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compounds may be prepared as a sterile solid composition which may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium. Carriers are intended to include necessary and inert binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.

The compound can be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents, for example, enough saline or glucose to make the solution isotonic, bile salts, acacia, gelatin, sorbitan monooleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.

The compound can also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.



Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular compound in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of administration.

10 In the subject invention a "therapeutically effective amount" is any amount of a compound which, when administered to a subject suffering from a disease against which the compounds are effective, causes reduction, remission, or regression of the disease. In one embodiment the therapeutically effective amount is an amount from about 0.01 mg per subject per day to about 500 mg per subject per day, preferably from about 0.1 mg per subject per day to about 60 mg per subject per day and most preferably from about 1 mg per subject per day to about 20 mg per subject per day.

This invention is directed to a transgenic nonhuman mammal expressing a nucleic acid of this invention.

25 This invention is directed to a transgenic nonhuman mammal comprising a homologous recombination knockout of a polypeptide expressed by a nucleic acid of this invention.

30 This invention is directed to a transgenic nonhuman mammal whose genome comprises antisense DNA complementary to a nucleic acid of this invention so placed as to be transcribed into antisense mRNA which is complementary to mRNA encoding a polypeptide and which hybridizes to mRNA encoding a polypeptide, thereby reducing its translation.

In one embodiment, the nucleic acid additionally

comprises an inducible promoter.

In another embodiment, the nucleic acid additionally comprises tissue specific regulatory elements.

5

In another embodiment, the transgenic nonhuman mammal is a mouse.

10 Animal model systems which elucidate the physiological and behavioral roles of the above-described polypeptides are produced by creating transgenic animals in which the activity of the polypeptide is either increased or decreased, or the amino acid sequence of the expressed  
15 polypeptide is altered, by a variety of techniques. Examples of these techniques include, but are not limited to: 1) Insertion of normal or mutant versions of DNA encoding the polypeptide, by microinjection, electroporation, retroviral transfection or other means  
20 well known to those skilled in the art, into appropriate fertilized embryos in order to produce a transgenic animal or 2) Homologous recombination of mutant or normal, human or animal versions of these genes with the native gene locus in transgenic animals to alter the  
25 regulation of expression or the structure of these polypeptide sequences. The technique of homologous recombination is well known in the art. It replaces the native gene with the inserted gene and so is useful for producing an animal that cannot express native  
30 polypeptide but does express, for example, an inserted mutant polypeptide, which has replaced the native polypeptide in the animal's genome by recombination, resulting in underexpression of the polypeptide. Microinjection adds genes to the genome, but does not  
35 remove them, and so is useful for producing an animal which expresses its own and added polypeptides, resulting in overexpression of the polypeptides.

One means available for producing a transgenic animal, with a mouse as an example, is as follows: Female mice are mated, and the resulting fertilized eggs are dissected out of their oviducts. The eggs are stored in an appropriate medium such as M2 medium. DNA or cDNA encoding a polypeptide is purified from a vector by methods well known in the art. Inducible promoters may be fused with the coding region of the DNA to provide an experimental means to regulate expression of the trans-gene. Alternatively or in addition, tissue specific regulatory elements may be fused with the coding region to permit tissue-specific expression of the trans-gene. The DNA, in an appropriately buffered solution, is put into a microinjection needle (which may be made from capillary tubing using a pipet puller) and the egg to be injected is put in a depression slide. The needle is inserted into the pronucleus of the egg, and the DNA solution is injected. The injected egg is then transferred into the oviduct of a pseudopregnant mouse (a mouse stimulated by the appropriate hormones to maintain pregnancy but which is not actually pregnant), where it proceeds to the uterus, implants, and develops to term. As noted above, microinjection is not the only method for inserting DNA into the egg cell, and is used here only for exemplary purposes.

This invention is directed to a process for identifying a chemical compound which specifically binds to a polypeptide of this invention, which comprises contacting the polypeptide with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the polypeptide.

In one embodiment, the specific binding of the compound to the polypeptide is detected by means of an antibody which binds to the polypeptide.

In another embodiment, the specific binding of the compound to the polypeptide is detected by a scintillation proximity assay.

5 In another embodiment, the polypeptide has substantially the same amino acid sequence as that shown in Figure 5.

In another embodiment, the compound is not previously known to bind to the polypeptide.

10

In another embodiment, the compound is determined by the process described above.

15 This invention is directed to a pharmaceutical composition which comprises an effective amount of a compound determined by the above-described process and a pharmaceutically acceptable carrier.

20 This invention is directed to a process involving competitive binding for identifying a chemical compound which specifically binds to a polypeptide of this invention which comprises separately contacting the polypeptide, with both the chemical compound and a second chemical compound known to bind to the polypeptide, and  
25 with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the polypeptide, a decrease in the binding of the second chemical compound to the polypeptide in the presence of  
30 the chemical compound indicating that the chemical compound binds to the polypeptide.

35 This invention is directed to a process of this invention, wherein the specific binding of the compound to the polypeptide is detected by means of an antibody which binds to the polypeptide.

In one embodiment, the specific binding of the compound to the polypeptide is detected by a scintillation proximity assay.

5 In another embodiment, the polypeptide has substantially the same amino acid sequence as that shown in Figure 5.

In another embodiment, the compound is not previously known to bind to the polypeptide.

10

This invention is directed to a compound determined by the above-described process.

15

This invention is directed to a pharmaceutical composition which comprises an effective amount of a compound determined by the above-described process and a pharmaceutically acceptable carrier.

20

This invention is directed to a process for identifying a chemical compound which specifically binds to a polypeptide encoded by a nucleic acid of this invention, which comprises contacting cells containing DNA encoding and expressing on the cell surface the polypeptide, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the polypeptide.

25

30

In one embodiment, wherein the polypeptide has substantially the same amino acid sequence as that shown in Figure 5.

In another embodiment, the compound is not previously known to bind to the polypeptide.

35

In another embodiment, the compound is determined by the above-described process.

In another embodiment, the pharmaceutical composition which comprises an effective amount of a compound determined by the above-described process and a pharmaceutically acceptable carrier.

5

In another embodiment, wherein the cell is an insect cell.

In another embodiment, the cell is a mammalian cell.

10

In another embodiment, the cell is nonneuronal in origin.

In another embodiment, the nonneuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell or an LM(tk-) cell.

15

This invention is directed to a process for identifying a chemical compound which specifically binds to a polypeptide encoded by a nucleic acid of this invention, which comprises contacting a membrane fraction from a cell extract of cells containing DNA encoding and expressing on their cell surface the polypeptide, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the polypeptide.

20

25

In one embodiment, the polypeptide has substantially the same amino acid sequence as that shown in Figure 5.

30

In another embodiment, the compound is not previously known to bind to the polypeptide.

In another embodiment, the compound is determined by the above-described process

35

This invention is directed to a pharmaceutical composition which comprises an effective amount of a

compound determined by the above-described process and a pharmaceutically acceptable carrier.

In one embodiment, the cell is an insect cell.

5

In another embodiment, the cell is a mammalian cell.

In another embodiment, the cell is nonneuronal in origin.

10 In another embodiment, the nonneuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell or an LM(tk-) cell.

15 This invention is directed to a process involving competitive binding for identifying a chemical compound which specifically binds to a polypeptide encoded by a nucleic acid of this invention, which comprises separately contacting cells expressing on their cell surface the polypeptide, with both the chemical compound and a second chemical compound known to bind to the polypeptide, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the polypeptide, a decrease in the binding of the second chemical compound to the polypeptide in the presence of the chemical compound indicating that the chemical compound binds to the polypeptide.

20 In one embodiment, the polypeptide has the amino acid sequence shown in Figure 5 (Seq. I.D. No. 10).

25 In another embodiment, the cell is an insect cell.

In another embodiment, the cell is a mammalian cell.

30

35 In another embodiment, the cell is nonneuronal in origin.

In another embodiment, the nonneuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell or an LM(tk-) cell.

- 5 In another embodiment, the compound is not previously known to bind to the polypeptide.

This invention is directed to a compound determined by the above-described process.

10

This invention is directed to a pharmaceutical composition which comprises an effective amount of a compound determined by the above-described process and a pharmaceutically acceptable carrier.

15

- This invention is directed to a process involving competitive binding for identifying a chemical compound which specifically binds to a polypeptide encoded by a nucleic acid of this invention, which comprises separately contacting a membrane fraction from a cell extract of cells expressing on their cell surface the polypeptide, with both the chemical compound and a second chemical compound known to bind to the polypeptide, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the polypeptide, a decrease in the binding of the second chemical compound to the polypeptide in the presence of the chemical compound indicating that the chemical compound binds to the polypeptide.
- 20
- 25
- 30

In one embodiment, the polypeptide has the amino acid sequence shown in Figure 5 (Seq. I.D. No. 10).

- 35 In another embodiment, the cell is an insect cell.

In another embodiment, the cell is a mammalian cell.



In another embodiment, the cell is nonneuronal in origin.

In another embodiment, the nonneuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell or an LM(tk-) cell.

In another embodiment, wherein the compound is not previously known to bind to the polypeptide.

10 This invention is directed to a compound determined by the process of this invention.

This invention is directed to a pharmaceutical composition which comprises an effective amount of a compound determined by the above-described process and a pharmaceutically acceptable carrier.

20 This invention is directed to a method of screening a plurality of chemical compounds not known to bind to a polypeptide encoded by a nucleic acid of this invention to identify a compound which specifically binds to the polypeptide, which comprises:

25 (a) contacting cells transfected with and expressing DNA encoding the polypeptide with a compound known to bind specifically to the polypeptide;

30 (b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically to the polypeptide, under conditions permitting binding of compounds known to bind the polypeptide;

35 (c) determining whether the binding of the compound known to bind to the polypeptide is reduced in the presence of the plurality of compounds,

relative to the binding of the compound in the absence of the plurality of compounds; and if so

- 5           (d) separately determining the binding to the polypeptide of each compound included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the polypeptide.

10

In one embodiment, the cell is a mammalian cell.

In another embodiment, the mammalian cell is non-neuronal in origin.

15

In another embodiment, the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an LM(tk-) cell or an NIH-3T3 cell.

20

This invention is directed to a pharmaceutical composition comprising an effective amount of a compound identified by the above-described method and a pharmaceutically acceptable carrier.

25

This invention is directed to a method of screening a plurality of chemical compounds not known to bind to a polypeptide of this invention to identify a compound which specifically binds to the polypeptide, which comprises:

30

- (a) preparing a cell extract or cell supernatant from cells transfected with and expressing DNA encoding the polypeptide and contacting the cell extract or cell supernatant with a compound known to bind specifically to the polypeptide;

35

5 (b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically to the polypeptide, under conditions permitting binding of compounds known to bind the polypeptide;

10 (c) determining whether the binding of the compound known to bind to the polypeptide is reduced in the presence of the compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so

15 (d) separately determining the binding to the polypeptide of each compound included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the polypeptide.

20 In one embodiment, the cell is a mammalian cell.

In another embodiment, the mammalian cell is non-neuronal in origin.

25 In another embodiment, the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an LM(tk-) cell or an NIH-3T3 cell.

30 This invention is directed to a pharmaceutical composition comprising an effective amount of a compound identified by the above-described method and a pharmaceutically acceptable carrier.

35 This invention is directed to a process for determining whether a chemical compound is an Ob receptor agonist which comprises contacting cells transfected with and expressing DNA of this invention with the compound under conditions permitting the activation of the Ob receptor,

and detecting an increase in Ob receptor activity, so as to thereby determine whether the compound is an Ob receptor agonist.

5 This invention is directed to a process for determining whether a chemical compound is an Ob receptor agonist which comprises preparing a cell extract from cells transfected with and expressing DNA of this invention, isolating a membrane fraction from the cell extract,  
10 contacting the membrane fraction with the compound under conditions permitting the activation of the Ob receptor, and detecting an increase in Ob receptor activity, so as to thereby determine whether the compound is an Ob receptor agonist.

15 This invention is directed to a process for determining whether a chemical compound is an Ob receptor antagonist which comprises contacting cells transfected with and expressing DNA of this invention with the compound in the presence of a known Ob receptor agonist, under conditions  
20 permitting the activation of an Ob receptor, and detecting a decrease in Ob receptor activity, so as to thereby determine whether the compound is an Ob receptor antagonist.

25 This invention is directed to a process for determining whether a chemical compound is an Ob receptor antagonist which comprises preparing a cell extract from cells transfected with and expressing DNA of this invention,  
30 isolating a membrane fraction from the cell extract, contacting the membrane fraction with the ligand in the presence of a known Ob receptor agonist, under conditions permitting the activation of the Ob receptor, and detecting a decrease in Ob receptor activity, so as to  
35 thereby determine whether the compound is an Ob receptor

antagonist.

In one embodiment, the Ob receptor is a mammalian Ob receptor.

5

In another embodiment, the cell is an insect cell.

In another embodiment, the cell is a mammalian cell.

10 In another embodiment, the cell is nonneuronal in origin.

In another embodiment, the nonneuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell or an LM(tk-) cell.

15

This invention is directed to a pharmaceutical composition comprising an effective amount of a polypeptide of this invention and a pharmaceutically acceptable carrier.

20

In one embodiment, the pharmaceutical composition is a liquid.

In another embodiment, the carrier is isotonic saline.

25

This invention is directed to a method for determining whether a compound modulates leptin activity which comprises:

30

(a) administering to an animal a polypeptide of this invention and measuring the amount of food intake, metabolic, or body weight changes in the animal;

35

(b) administering to a second animal both the polypeptide and the compound, and measuring the

amount of food intake, metabolic, or body weight changes in the second animal; and

- 5 (c) determining whether the amount of food intake, metabolic, or body weight change is altered in the presence of the compound relative to the amount of food intake, metabolic, or body weight change in the absence of the compound, so as to thereby determine whether the compound  
10 modulates leptin activity.

This invention is directed to a method of screening a plurality of compounds to identify a compound which modulates leptin activity which comprises:

- 15 (a) administering to an animal a polypeptide of this invention and measuring the amount of food intake, metabolic, or body weight changes in the animal;
- 20 (b) administering to a second animal the polypeptide and at least one compound of the plurality of compounds and measuring the amount of food intake, metabolic, or body weight changes in the animal;
- 25 (c) determining whether the amount of food intake, metabolic, or body weight change is altered in the presence of at least one compound of the plurality relative to the amount of food intake, metabolic, or body weight change in the absence of at least one compound of the plurality, and if so;
- 30 (d) separately determining whether each compound modulates leptin activity according to the above-described method, so as to thereby
- 35

identify a compound which modulates leptin activity.

5 This invention is directed to a method of treating an abnormality in a subject, wherein the abnormality is alleviated by modulating the activity of leptin in the subject, which comprises administering to a subject an amount of the pharmaceutical composition of this invention effective to modulate the activity of leptin in  
10 the subject, thereby treating the abnormality in the subject.

15 In one embodiment, the pharmaceutical composition is administered with food.

In another embodiment, the subject is a vertebrate, a mammal, a human, a canine or a feline.

20 In another embodiment, the pharmaceutical composition comprises an injectable carrier.

In another embodiment, the pharmaceutical composition comprises a wild-type polypeptide.

25 This invention is directed to a method of modulating feeding behavior or metabolism of a subject which comprises administering to the subject an amount of a polypeptide of this invention effective to modulate the feeding behavior or metabolism of the subject so as to  
30 thereby modulate feeding behavior or metabolism of the subject.

In one embodiment, the subject's anorexia is treated.

35 In another embodiment, the subject's weight loss associated with cancer is treated.

In another embodiment, the subject's reduced appetite associated with aging is treated.

In another embodiment, the subject's obesity is treated.

5

In another embodiment, the subject's bulimia is treated.

In another embodiment, the compound is administered with food.

10

In another embodiment, the subject is a vertebrate, a mammal, a human, a canine or a feline.

In another embodiment, the polypeptide is administered in a pharmaceutical composition comprising an injectable carrier.

15

In another embodiment, the polypeptide is a wild-type polypeptide.

20

This invention is directed to a method of modulating feeding behavior or metabolism of a subject which comprises administering a polypeptide of this invention and a compound which binds to the Y5 receptor, the amount of such polypeptide and compound being effective to modulate the feeding behavior or metabolism of the subject.

25

In one embodiment, the polypeptide and the compound are administered in combination.

30

In another embodiment, the polypeptide and the compound are administered separately.

35

In another embodiment, the polypeptide and the compound are administered once.



In another embodiment, the polypeptide and the compound are administered alternately.

5 In another embodiment, the polypeptide and the compound are administered repeatedly.

In another embodiment, the polypeptide and compound are administered with food.

10 In another embodiment, the subject is a vertebrate, a mammal, a human, a canine or a feline.

15 In another embodiment, the polypeptide and compound are administered in a pharmaceutical composition comprising an injectable carrier.

In another embodiment, the polypeptide is a wild-type polypeptide.

20 This invention is directed to a method of modulating feeding behavior or metabolism in a subject which comprises administering to the subject an amount of a compound which binds to a polypeptide of the invention effective to alter the activity of leptin in the subject,  
25 so as to thereby modulate feeding behavior or metabolism of the subject.

30 In one embodiment, the subject's anorexia is treated.

In another embodiment, the subject's weight loss associated with cancer is treated.

35 In another embodiment, the subject's reduced appetite associated with aging is treated.

In another embodiment, the subject's obesity is treated.

In another embodiment, the subject's bulimia is treated.

In another embodiment, the compound is administered with food.

5

In another embodiment, the subject is a vertebrate, a mammal, a human, a canine or a feline.

10

In another embodiment, the compound is administered in a pharmaceutical composition comprising an injectable carrier.

15

In another embodiment, the polypeptide is a wild-type polypeptide.

20

This invention is directed to a method of modulating feeding behavior or metabolism of a subject which comprises administering a compound which binds to a polypeptide of the invention and a second compound which binds to the Y5 receptor, the amount of the first compound and the second compound being effective to modulate the feeding behavior or metabolism of the subject.

25

In one embodiment, the compound and the second compound are administered in combination.

30

In another embodiment, the compound and the second compound are administered separately.

35

In another embodiment, the compound and the second compound are administered once.

In another embodiment, the compound and the second compound are administered alternately.

In another embodiment, the compound and the second

compound are administered repeatedly.

In another embodiment, the compound and second compound are administered with food.

5

In another embodiment, the subject is a vertebrate, a mammal, a human, a canine or a feline.

10

In another embodiment, the compound and second compound are administered in a pharmaceutical composition comprising an injectable carrier.

15

In another embodiment, the polypeptide is a wild-type polypeptide.

20

This invention is directed to a method of detecting expression of a polypeptide of this invention by detecting the presence of mRNA coding for the polypeptide which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with the nucleic acid probe of this invention under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of the polypeptide by the cell.

25

This invention is directed to a method of detecting the presence of a polypeptide which comprises contacting the cell or cell supernatant with the antibody of this invention under conditions permitting binding of the antibody to the polypeptide, detecting the presence of the antibody bound to the cell or cell supernatant, and thereby detecting the presence of a polypeptide.

30

35

This invention is directed to a method of determining the physiological effects of varying levels of activity of polypeptides which comprises producing a transgenic nonhuman mammal of this invention whose levels of

polypeptide activity are varied by use of an inducible promoter which regulates polypeptide expression.

5 This invention is directed to a method of determining the physiological effects of varying levels of activity of polypeptides which comprises producing a panel of transgenic nonhuman mammals of this invention each expressing a different amount of polypeptide.

10 This invention is directed to a method for diagnosing a predisposition to a disorder associated with the activity of a specific polypeptide allele which comprises:

- 15 (a) obtaining DNA of subjects suffering from the disorder;
- (b) performing a restriction digest of the DNA with a panel of restriction enzymes;
- 20 (c) electrophoretically separating the resulting DNA fragments on a sizing gel;
- (d) contacting the resulting gel with a nucleic acid probe capable of specifically hybridizing with a unique sequence included within the sequence of a nucleic acid molecule encoding a polypeptide and labeled with a detectable marker;
- 25 (e) detecting labeled bands which have hybridized to the nucleic acid of this invention labeled with a detectable marker to create a unique band pattern specific to the DNA of subjects suffering from the disorder;
- 30 (f) preparing DNA obtained for diagnosis by steps a-e; and
- 35

(g) comparing the unique band pattern specific to the DNA of subjects suffering from the disorder from step e and the DNA obtained for diagnosis from step f to determine whether the patterns are the same or different and to diagnose thereby predisposition to the disorder if the patterns are the same.

In one embodiment, the disorder associated with the activity of a specific polypeptide allele is diagnosed.

This invention is directed to a method of preparing the purified polypeptide this invention which comprises:

- (a) inducing cells to express the polypeptide;
- (b) recovering the polypeptide from the induced cells; and
- (c) purifying the polypeptide so recovered.

In one embodiment, the cell is placed in a serum-free growth medium.

In another embodiment, the polypeptide is recovered by affinity chromatography.

In another embodiment, the affinity chromatography comprises the use of leptin.

In another embodiment, the polypeptide is recovered by means of antibody binding.

In another embodiment, the antibody is directed to a flag epitope modification of the wild-type polypeptide.

This invention is directed to a method of preparing the

purified polypeptide of this invention which comprises:

- 5
- (a) inserting nucleic acid encoding the polypeptide in a suitable vector;
  - (b) introducing the resulting vector in a suitable host cell;
  - 10 (c) placing the resulting cell in suitable condition permitting the production of the isolated polypeptide;
  - (d) recovering the polypeptide produced by the resulting cell; and
  - 15 (e) purifying the polypeptide so recovered.

In one embodiment, the cell is placed in a serum-free growth medium.

20 In another embodiment, the polypeptide is recovered by affinity chromatography.

25 In another embodiment, the affinity chromatography comprises the use of leptin.

In another embodiment, the polypeptide is recovered by means of antibody binding.

30 In another embodiment, the antibody is directed to a flag epitope modification of the wild-type polypeptide.

35 This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which

follow thereafter.

60416676.0/1698

## Experimental Details

### **Materials and Methods**

#### Cloning and Sequencing a novel human Ob-Re receptor

5

#### 3' RACE of human RNAs for hOb-Re

3' RACE (rapid analysis of cDNA ends) was performed on human kidney, liver, skeletal muscle, heart, adipose and lung RNAs using a Marathon cDNA Amplification Kit (Clontech). Total RNA was prepared from human adipose tissue using RNAgents Total RNA Isolation System (Promega). For other tissues, total RNA was purchased from Clontech. All total RNAs were poly A+ selected using a FastTrack mRNA Isolation Kit (Invitrogen Corp., San Diego, CA). For 3' RACE, double stranded (ds) cDNA synthesis, adaptor ligation and nested PCR were performed according to the Marathon cDNA Amplification protocol. The initial PCR reaction was performed on 1  $\mu$ L of a 50 fold dilution of the ligated cDNA using the supplier's Adaptor Primer 1 (AP1) and one of the following gene-specific primers (GSP): DC17, BB75 or BB76. One  $\mu$ L of this initial PCR reaction was re-amplified using Adaptor Primer 2 (AP2) and one of the following GSPs: DC18, DC4, BB76 or BB87. PCR was carried out using an Advantage KlenTaq Polymerase Kit (Clontech) under the following conditions: 30 sec at 94°C, 4 min at 72°C for 5 cycles, 30 sec at 94°C, 4 min at 70°C for 5 cycles, 20 sec at 94°C, 4 min at 68°C for 25 cycles (for first PCR) or 18 cycles (for nested PCR), with a pre- and post-incubation of 1 min at 94°C and 7 min at 68°C, respectively. Bands from the nested PCR were isolated from TAE gels using a GENECLAN III kit (BIO 101, Vista, CA) and sequenced using AmpliTaq DNA Polymerase, FS (Perkin Elmer). The sequences were run on an ABI PRISM 377 DNA Sequencer and analyzed using the Wisconsin Package (GCG, Genetics Computer Group, Madison, WI).



#### Low Stringency PCR for hOb-Re

PCR was performed on cDNAs from human kidney, liver, skeletal muscle and heart using a forward primer from hOb-Rb (DC4) and a reverse primer from the mouse Ob-Re sequence (BB116). PCR was carried out using both the Expand Long Template PCR System and the Expand High Fidelity System (Boehringer Mannheim) under the following conditions: 1 min at 94°C, 2 min at 42°C, 4 min at 68°C for 36 cycles, with a pre- and post-incubation of 4 min at 94°C and 10 min at 68°C, respectively.

#### Identification of Human Ob-Re-Specific Sequence

Mouse genomic DNA (100 ng, Clontech) was amplified using forward (BB130) and reverse (BB131) PCR primers from mouse Ob-Rb. Human genomic DNA (100 ng, Clontech) was amplified using forward (DC4) and reverse (BB132) PCR primers from human Ob-Rb. PCR was carried out using the Expand Long Template PCR System (Boehringer Mannheim) under the following conditions: 1 min at 92 ° C, 2 min at 60°C, 10 min at 68°C for 30 cycles, with a pre- and post-incubation of 4 min at 92°C and 10 min at 68°C, respectively. A 9.5 kb band from mouse and a 2.2 kb band from human were isolated from a 1% TAE gel using a GENECLEAN III kit (BIO 101, Vista, CA) and sequenced using AmpliTaq DNA Polymerase, FS (Perkin Elmer). The sequence was run on an ABI PRISM 377 DNA Sequencer and analyzed using the Wisconsin Package (GCG, Genetics Computer Group, Madison, WI). The sequence of this piece was identical to the human Ob-Rb receptor from primer DC4 up to nucleotide 2495, after which it diverged completely from any of the published human Ob receptors. This novel sequence contained an open reading frame encoding 6 amino acids, and shares 83% nucleotide identity to the mouse Ob-Re.

#### Localization of Ob-Re in human tissues

RT-PCR was used to identify human tissues that express

hOb-Re, using the forward primer DC4 and a reverse primer from hOb-Re, BB138. PCR was carried out using the Expand Long Template PCR System (Boehringer Mannheim) under the following conditions: 1 min at 94°C, 2 min at 62°C, 2 min at 68°C for 30 cycles, with a pre- and post-incubation of 5 min at 94°C and 10 min at 68°C, respectively. The templates used were cDNA from hypothalamus, total brain, heart, kidney, skeletal muscle, liver, lung and adipose as well as RACE reactions from heart, skeletal muscle, adipose and lung which had been amplified previously with primers DC17 and AP1 (see above). A 0.2 kb band was amplified from the lung RACE product. To verify that this 0.2 kb product from lung was derived from mRNA and was not a genomic DNA contamination, we amplified human lung cDNA with a forward PCR primer from hOb-Rb (DC16) and a reverse primer from hOb-Re (BB139) and then reamplified one  $\mu$ L of this product with primers DC16 and BB138. A 2 kb and a 0.26 kb band were isolated from a 1 % TAE gel using a GENECLEAN III kit (BIO 101, Vista, CA) and partially sequenced using AmpliTaq DNA Polymerase, FS (Perkin Elmer). The sequence was run on an ABI PRISM 377 DNA Sequencer and analyzed using the Wisconsin Package (GCG, Genetics Computer Group, Madison, WI). The 2 kb band contained an intron while the 0.26 kb band contained the sequence for the 3' end of the hOb-Re receptor. In contrast, when DC16 and BB138 were used to amplify human genomic DNA, only a 2 kb band was isolated.

#### Preparation of full-length hOb-Re construct

A 2.4 kb ClaI-EarI fragment encoding nucleotides 1 to 2371 of hOb-Rb, was isolated from a hOb-Rb construct in the vector pEXJ. Two overlapping oligonucleotides (BB157 and BB158) were synthesized, corresponding to nucleotides 2372 to 2395 of hOb-Rb and nucleotides 2396-2415 of hOb-Re, and incorporating a digested EarI site at the 5' end and a digested HindIII site at the 3' end. A full-length hOb-Re construct, designated BO25, was obtained by

ligating the ClaI-EarI fragment and the oligonucleotide to the vector pEXJ cut with ClaI and HindIII and has been deposited with the ATCC (ATCC Accession No. 209036).

5     Transient transfection in COS-7 cells

COS-7 cells are grown on 150 mm plates in DMEM with supplements (Dulbecco's Modified Eagle Medium with 10% bovine calf serum, 4 mM glutamine, 100 units/mL penicillin, 100 µg/mL streptomycin) at 37 ° C, 5% CO<sub>2</sub>.  
10     Stock plates of COS-7 cells are trypsinized and split 1:6 every 3-4 days. hOb-Re (BO25) was transiently transfected into COS-7 cells by the DEAE dextran method, using 20 µg DNA / T150 flask (Cullen, 1987). Transfected cells were plated in 96-well plates in 100 ul medium.

15     Scintillation Proximity Assay

100 ul of binding buffer (composition: CaCl<sub>2</sub>, 1.2 mM; Hepes, 20 mM; NaCl, 9.9 mM; KCl 5.4 mM; KH<sub>2</sub>PO<sub>4</sub>, 0.44 mM; MgSO<sub>4</sub>, 0.81 mM) containing 0.1 nM [<sup>125</sup>I]leptin and 1.0%  
20     BSA were added to each well of a 96-well plate containing hOb-Re-transfected COS-7 cells. Finally, 50 µl of SPA beads (Amersham International, England; 20 mg/mL in binding buffer) were added to each well and the cells were incubated for 24 hrs at room temperature on a  
25     shaking rotor. 200 µL aliquots were removed from each well and counted in scintillation counter at 80% efficiency. Other cells expressing hOb-Re and supernatant (e.g., culture medium) from such cells may also be used for binding assays, such as insect cells and  
30     their supernatants, amphibian cells or other mammalian cells described herein.

Competitive binding assays may be performed similarly, wherein the displacement of [<sup>125</sup>I]leptin by a test compound  
35     is evaluated by separately measuring the binding of [<sup>125</sup>I]leptin in the presence of, and in the absence of, the test compound. Multiple concentrations of test compound

may be also be used, to determine the  $IC_{50}$  of the compound with respect to leptin (or other ligands known to bind to Ob receptors) according to methods well known in the art. In addition, determination of the  $K_d$  of leptin for hOb-Re may also be accomplished using SPA detection, such that Ki's may be calculated using the method of Cheng and Prusoff (1973). Additional methods of detecting specific binding include using gel filtration, affinity columns, or radioimmunoassay utilizing an antibody to the receptor.

#### Production of recombinant baculovirus

Recombinant baculovirus expressing hOb-Re was generated using the Bac-to-Bac Baculovirus Expression System (Gibco BRL). A SacI/HindIII fragment containing the entire encoding region of hOb-Re was isolated from BO25, and ligated to the vector pFastBacI at the SacI and HindIII sites. A second construct was made, using a Chameleon Double-Stranded Site-Directed Mutagenesis Kit (Stratagene), which differed in that it contained an 8 amino acid flag epitope (Kodak) downstream of the signal sequence cleavage site in hOb-Re. Recombinant bacmid E.coli colonies were generated and DNA for each was isolated as described by the manufacturer. The constructs with and without the flag epitope are designated BO47 and BO45, respectively.

#### Transfection of recombinant bacmid DNA into SF21 cells

SF21 cells (Invitrogen) are grown in T75 flasks in TMN-FH Insect Medium (PharMingen) at 27°C without  $CO_2$  supplementation. Stock plates of SF21 cells are gently dislodged under a stream of media and split 1:4 every 2-3 days. SF21 cells grown in 6-well plates were transfected with recombinant bacmid DNA, BO45 or BO47, using CellFECTIN Reagent (Gibco BRL) as described by the manufacturer. Virus-containing supernatants were collected 96 and 144 hours after transfection.

#### Amplification of viral stock

SF21 cells grown in 6-well plates were infected with the viral supernatant from the BO45-transfected cells above at 1,  $10^{-1}$ ,  $10^{-2}$ ,  $10^{-3}$ ,  $10^{-4}$  and  $10^{-5}$  dilutions. Supernatants from these were collected 120 hours after infection. To determine the viral titer of the amplified stock, a viral plaque assay was performed on supernatant from the  $10^{-1}$  dilution-infected cells, designated P3- $10^{-1}$ , according to protocol for BaculoGold Baculovirus kit (PharMingen). 500 mL of high-titer viral stock was generated by infecting SF21 cells in T150 flasks with the supernatant from P3- $10^{-1}$  at a multiplicity of infection (MOI) of 0.1 and collecting supernatant 120 hours after infection. This supernatant was designated Bac-BO45 and deposited with the ATCC (ATCC Accession No. VR-2574). To optimize the MOI and the time course for leptin binding studies, SF21 cells in 6-well were infected with the supernatant from P3- $10^{-1}$  at MOIs of 1, 2, 5 and 10 and supernatant collected at 48, 72, 96 and 120 hours.

#### Cell Culture

In addition to the COS-7 cells described above, other cells may be transfected with the hOb-Re receptor using standard methods.

Human embryonic kidney 293 cells are grown on 150 mm plates in D-MEM with supplements (minimal essential medium) with Hanks' salts and supplements (Dulbecco's Modified Eagle Medium with 10% bovine calf serum, 4 mM glutamine, 100 units/mL penicillin/100  $\mu$ g/mL streptomycin) at 37°C, 5% CO<sub>2</sub>. Stock plates of 293 cells are trypsinized and split 1:6 every 3-4 days. Mouse fibroblast LM(tk-) cells are grown on 150 mm plates in D-MEM with supplements (Dulbecco's Modified Eagle Medium with 10% bovine calf serum, 4 mM glutamine, 100 units/mL penicillin/100  $\mu$ g/mL streptomycin) at 37°C, 5% CO<sub>2</sub>. Stock plates of LM(tk-) cells are trypsinized and split 1:10

every 3-4 days.

LM(tk-) cells stably transfected with the human Ob-Re  
receptor may be routinely converted from an adherent  
5 monolayer to a viable suspension. Adherent cells are  
harvested with trypsin at the point of confluence,  
resuspended in a minimal volume of complete DMEM for a  
cell count, and further diluted to a concentration of  $10^6$   
10 cells/mL in suspension media (10% bovine calf serum, 10%  
10X Medium 199 (Gibco), 9 mM  $\text{NaHCO}_3$ , 25 mM glucose, 2 mM  
L-glutamine, 100 units/mL penicillin/100  $\mu\text{g/mL}$   
streptomycin, and 0.05% methyl cellulose). Cell  
suspensions are maintained in a shaking incubator at  
37°C, 5%  $\text{CO}_2$  for 24 hours. Membranes harvested from cells  
15 grown in this manner may be stored as large, uniform  
batches in liquid nitrogen. Alternatively, cells may be  
returned to adherent cell culture in complete DMEM by  
distribution into 96-well microtiter plates coated with  
poly-D-lysine (0.01 mg/mL) followed by incubation at  
20 37°C, 5%  $\text{CO}_2$  for 24 hours.

Mouse embryonic fibroblast NIH-3T3 cells are grown on 150  
mm plates in Dulbecco's Modified Eagle Medium (DMEM) with  
supplements (10% bovine calf serum, 4 mM glutamine, 100  
25 units/mL penicillin/100  $\mu\text{g/mL}$  streptomycin) at 37°C, 5%  
 $\text{CO}_2$ . Stock plates of NIH-3T3 cells are trypsinized and  
split 1:15 every 3-4 days. Chinese hamster ovary (CHO)  
cells are grown on 150 mm plates in HAM's F-12 medium  
with supplements (10% bovine calf serum, 4 mM L-glutamine  
30 and 100 units/mL penicillin/100  $\mu\text{g/mL}$  streptomycin) at  
37°C, 5%  $\text{CO}_2$ . Stock plates of CHO cells are trypsinized  
and split 1:8 every 3-4 days.

Sf9 and Sf21 cells are grown in monolayers on 150 mm  
35 tissue culture dishes in TMN-FH media supplemented with  
10% fetal calf serum, at 27°C, no  $\text{CO}_2$ . High Five insect  
cells are grown on 150 mm tissue culture dishes in Ex-

Cell 400™ medium supplemented with L-Glutamine, also at 27°C, no CO<sub>2</sub>.

#### Transfection

- 5 The receptors described herein may be transiently transfected into COS-7 cells by the DEAE-dextran method, using 1 µg of DNA /10<sup>6</sup> cells (Cullen, 1987). In addition, Schneider 2 Drosophila cells may be cotransfected with vectors containing the receptor gene, under control of a promoter which is active in insect cells, and a selectable resistance gene, eg., the G418 resistant neomycin gene, for expression of the human Ob-Re receptor.

#### Stable Transfection

- 15 The human Ob-Re receptor may be co-transfected with a G-418 resistant gene into the human embryonic kidney 293 cell line by a calcium phosphate transfection method (Cullen, 1987). Stably transfected cells are selected with G-418. Human Ob-Re receptors may be similarly transfected into mouse fibroblast LM(tk-) cells, Chinese hamster ovary (CHO) cells and NIH-3T3 cells, or other suitable host cells.

#### Membrane Preparations

- 25 LM(tk-) cells stably transfected with the DNA encoding the mammalian receptors disclosed herein may be routinely converted from an adherent monolayer to a viable suspension. Adherent cells are harvested with trypsin at the point of confluence, resuspended in a minimal volume of complete DMEM for a cell count, and further diluted to a concentration of 10<sup>6</sup> cells/ml in suspension media (10% bovine calf serum, 10% 10X Medium 199 (Gibco), 9 mM NaHCO<sub>3</sub>, 25 mM glucose, 2 mM L-glutamine, 100 units/ml penicillin/100 µg/ml streptomycin, and 0.05% methyl cellulose). Cell suspensions are maintained in a shaking incubator at 37°C, 5% CO<sub>2</sub> for 24 hours. Membranes

harvested from cells grown in this manner may be stored as large, uniform batches in liquid nitrogen. Alternatively, cells may be returned to adherent cell culture in complete DMEM by distribution into 96-well microtiter plates coated with poly-D-lysine (0.01 mg/ml) followed by incubation at 37°C, 5% CO<sub>2</sub> for 24 hours.

#### Radioligand binding assays

Transfected cells from culture flasks are scraped into 5 ml of Tris-HCl, 5mM EDTA, pH 7.5, and lysed by sonication. The cell lysates are centrifuged at 1000 rpm for 5 min. at 4°C, and the supernatant is centrifuged at 30,000 x g for 20 min. at 4°C. The pellet is suspended in binding buffer (50 mM Tris-HCl, 5 mM MgSO<sub>4</sub>, 1 mM EDTA at pH 7.5 supplemented with 0.1% BSA, 2 µg/ml aprotinin, 0.5 mg/ml leupeptin, and 10 µg/ml phosphoramidon). Optimal membrane suspension dilutions, defined as the protein concentration required to bind less than 10% of the added radioligand, are added to 96-well polpropylene microtiter plates containing <sup>3</sup>H-labeled compound, unlabeled compounds, and binding buffer to a final volume of 250 µl. In equilibrium saturation binding assays membrane preparations are incubated in the presence of increasing concentrations of [<sup>3</sup>H]-labeled compound. The binding affinities of the different compounds are determined in equilibrium competition binding assays, using [<sup>3</sup>H]-labeled compound in the presence of ten to twelve different concentrations of the displacing ligands. Binding reaction mixtures are incubated for 1 hr at 30°C, and the reaction stopped by filtration through GF/B filters treated with 0.5% polyethyleneimine, using a cell harvester. Radioactivity may be measured by scintillation counting and data are analyzed by a computerized non-linear regression program. Non-specific binding is defined as the amount of radioactivity remaining after incubation of membrane protein in the presence of unlabeled. Protein concentration may be



measured by the Bradford method using Bio-Rad Reagent, with bovine serum albumin as a standard.

### Functional assays

5

#### Cyclic AMP (cAMP) formation assay

The receptor-mediated inhibition of cyclic AMP (cAMP) formation may be assayed in transfected cells expressing the mammalian receptors described herein. Cells are  
10 plated in 96-well plates and incubated in Dulbecco's phosphate buffered saline (PBS) supplemented with 10 mM HEPES, 5mM theophylline, 2  $\mu$ g/ml aprotinin, 0.5 mg/ml leupeptin, and 10  $\mu$ g/ml phosphoramidon for 20 min at 37°C, in 5% CO<sub>2</sub>. Test compounds are added and incubated  
15 for an additional 10 min at 37°C. The medium is then aspirated and the reaction stopped by the addition of 100 mM HCl. The plates are stored at 4°C for 15 min, and the cAMP content in the stopping solution measured by radioimmunoassay. Radioactivity may be quantified using  
20 a gamma counter equipped with data reduction software.

#### Arachidonic acid release assay

Stably transfected cells with the mammalian receptors described herein are seeded into 96 well plates and grown  
25 for 3 days in HAM's F-12 with supplements. <sup>3</sup>H-arachidonic acid (specific activity = 0.75  $\mu$ Ci/ml) is delivered as a 100  $\mu$ L aliquot to each well and samples were incubated at 37°C, 5% CO<sub>2</sub> for 18 hours. The labeled cells are washed three times with 200  $\mu$ L HAM's F-12. The wells are then  
30 filled with medium (200  $\mu$ L) and the assay is initiated with the addition of peptides or buffer (22  $\mu$ L). Cells are incubated for 30 min at 37°C, 5% CO<sub>2</sub>. Supernatants are transferred to a microtiter plate and evaporated to dryness at 75°C in a vacuum oven. Samples are then  
35 dissolved and resuspended in 25  $\mu$ L distilled water. Scintillant (300  $\mu$ L) is added to each well and samples are counted for <sup>3</sup>H in a Trilux plate reader. Data are

analyzed using nonlinear regression and statistical techniques available in the GraphPAD Prism package (San Diego, CA).

5 Intracellular calcium mobilization assay

The intracellular free calcium concentration may be measured by microspectrofluorometry using the fluorescent indicator dye Fura-2/AM (Bush et al, 1991). Stably transfected cells are seeded onto a 35 mm culture dish containing a glass coverslip insert. Cells are washed with HBS and loaded with 100  $\mu$ L of Fura-2/AM (10  $\mu$ M) for 20 to 40 min. After washing with HBS to remove the Fura-2/AM solution, cells are equilibrated in HBS for 10 to 20 min. Cells are then visualized under the 40X objective of a Leitz Fluovert FS microscope and fluorescence emission is determined at 510 nm with excitation wavelengths alternating between 340 nm and 380 nm. Raw fluorescence data are converted to calcium concentrations using standard calcium concentration curves and software analysis techniques.

Phosphoinositide metabolism assay

Cells stably expressing the mammalian receptor cDNA described herein are plated in 96-well plates and grown to confluence. The day before the assay the growth medium is changed to 100  $\mu$ L of medium containing 1% serum and 0.5  $\mu$ Ci [ $^3$ H]myo-inositol, and the plates are incubated overnight in a CO<sub>2</sub> incubator (5% CO<sub>2</sub> at 37°C). Alternatively, arachidonic acid release may be measured if [ $^3$ H]arachidonic acid is substituted for the [ $^3$ H]myo-inositol. Immediately before the assay, the medium is removed and replaced by 200  $\mu$ L of PBS containing 10 mM LiCl, and the cells are equilibrated with the new medium for 20 min. During this interval cells are also equilibrated with the antagonist, added as a 10  $\mu$ L aliquot of a 20-fold concentrated solution in PBS. The [ $^3$ H]inositol-phosphates accumulation from inositol

phospholipid metabolism may be started by adding 10  $\mu$ L of a solution containing the agonist. To the first well 10  $\mu$ L may be added to measure basal accumulation, and 11 different concentrations of agonist are assayed in the following 11 wells of each plate row. All assays are performed in duplicate by repeating the same additions in two consecutive plate rows. The plates are incubated in a CO<sub>2</sub> incubator for 1 hr. The reaction may be terminated by adding 15  $\mu$ L of 50% v/v trichloroacetic acid (TCA), followed by a 40 min. incubation at 4 °C. After neutralizing TCA with 40  $\mu$ L of 1 M Tris, the content of the wells may be transferred to a Multiscreen HV filter plate (Millipore) containing Dowex AG1-X8 (200-400 mesh, formate form). The filter plates are prepared adding 200  $\mu$ L of Dowex AG1-X8 suspension (50% v/v, water: resin) to each well. The filter plates are placed on a vacuum manifold to wash or elute the resin bed. Each well is washed 2 times with 200  $\mu$ L of water, followed by 2 x 200  $\mu$ L of 5 mM sodium tetraborate/60 mM ammonium formate. The [<sup>3</sup>H]IPs are eluted into empty 96-well plates with 200  $\mu$ L of 1.2 M ammonium formate/0.1 formic acid. The content of the wells is added to 3 ml of scintillation cocktail, and the radioactivity is determined by liquid scintillation counting.

25

#### GTP $\gamma$ S functional assay

Membranes from cells transfected with the mammalian receptors described herein are suspended in assay buffer (50 mM Tris, 100 mM NaCl, 5 mM MgCl<sub>2</sub>, pH 7.4) supplemented with 0.1% BSA, 0.1% bacitracin and 10  $\mu$ M GDP. Membranes are incubated on ice for 20 minutes, transferred to a 96-well Millipore microtiter GF/C filter plate and mixed with GTP $\gamma$ <sup>35</sup>S (e.g., 250,000 cpm/sample, specific activity ~1000 Ci/mmol) plus or minus GTP $\gamma$ S (final concentration = 100  $\mu$ M). Final membrane protein concentration = 90  $\mu$ g/ml. Samples are incubated in the presence or absence of porcine galanin

35

(final concentration = 1  $\mu$ M) for 30 min. at room temperature, then filtered on a Millipore vacuum manifold and washed three times with cold assay buffer. Samples collected in the filter plate are treated with scintillant and counted for  $^{35}\text{S}$  in a Trilux (Wallace) liquid scintillation counter. It is expected that optimal results are obtained when the mammalian receptor membrane preparation is derived from an appropriately engineered heterologous expression system, i.e., an expression system resulting in high levels of expression of the mammalian receptor described herein and/or expressing G-proteins having high turnover rates (for the exchange of GDP for GTP). GTP $\gamma$ S assays are well-known in the art, and it is expected that variations on the method described above, such as are described by e.g., Tian et al. (1994) or Lazareno and Birdsall (1993), may be used by one of ordinary skill in the art.

#### MAP kinase assay

MAP kinase (mitogen activated kinase) may be monitored to evaluate receptor activation. MAP kinase is activated by multiple pathways in the cell. A primary mode of activation involves the ras/raf/MEK/MAP kinase pathway. Growth factor (tyrosine kinase) receptors feed into this pathway via SHC/Grb-2/SOS/ras. Gi coupled receptors are also known to activate ras and subsequently produce an activation of MAP kinase. Receptors that activate phospholipase C (Gq and G11) produce diacylglycerol (DAG) as a consequence of phosphatidyl inositol hydrolysis. DAG activates protein kinase C which in turn phosphorylates MAP kinase.

MAP kinase activation can be detected by several approaches. One approach is based on an evaluation of the phosphorylation state, either unphosphorylated (inactive) or phosphorylated (active). The phosphorylated protein has a slower mobility in SDS-PAGE

and can therefore be compared with the unstimulated protein using Western blotting. Alternatively, antibodies specific for the phosphorylated protein are available (New England Biolabs) which can be used to detect an increase in the phosphorylated kinase. In either method, cells are stimulated with the mitogen and then extracted with Laemmli buffer. The soluble fraction is applied to an SDS-PAGE gel and proteins are transferred electrophoretically to nitrocellulose or Immobilon. Immunoreactive bands are detected by standard Western blotting technique. Visible or chemiluminescent signals are recorded on film and may be quantified by densitometry.

Another approach is based on evaluation of the MAP kinase activity via a phosphorylation assay. Cells are stimulated with the mitogen and a soluble extract is prepared. The extract is incubated at 30°C for 10 min with gamma-32-ATP, an ATP regenerating system, and a specific substrate for MAP kinase such as phosphorylated heat and acid stable protein regulated by insulin, or PHAS-I. The reaction is terminated by the addition of  $H_2PO_4$  and samples are transferred to ice. An aliquot is spotted onto Whatman P81 chromatography paper, which retains the phosphorylated protein. The chromatography paper is washed and counted for  $^{32}P$  in a liquid scintillation counter. Alternatively, the cell extract is incubated with gamma-32-ATP, an ATP regenerating system, and biotinylated myelin basic protein bound by streptavidin to a filter support. The myelin basic protein is a substrate for activated MAP kinase. The phosphorylation reaction is carried out for 10 min at 30°C. The extract can then be aspirated through the filter, which retains the phosphorylated myelin basic protein. The filter is washed and counted for  $^{32}P$  by liquid scintillation counting.

#### Cell proliferation assay

Receptor activation of a G protein coupled receptor may lead to a mitogenic or proliferative response which can be monitored via  $^3\text{H}$ -thymidine uptake. When cultured cells are incubated with  $^3\text{H}$ -thymidine, the thymidine translocates into the nuclei where it is phosphorylated to thymidine triphosphate. The nucleotide triphosphate is then incorporated into the cellular DNA at a rate that is proportional to the rate of cell growth. Typically, cells are grown in culture for 1-3 days. Cells are forced into quiescence by the removal of serum for 24 hrs. A mitogenic agent is then added to the media. 24 hrs later, the cells are incubated with  $^3\text{H}$ -thymidine at specific activities ranging from 1 to 10  $\mu\text{Ci}/\text{ml}$  for 2-6 hrs. Harvesting procedures may involve trypsinization and trapping of cells by filtration over GF/C filters with or without a prior incubation in TCA to extract soluble thymidine. The filters are processed with scintillant and counted for  $^3\text{H}$  by liquid scintillation counting. Alternatively, adherent cells are fixed in MeOH or TCA, washed in water, and solubilized in 0.05% deoxycholate/0.1 N NaOH. The soluble extract is transferred to scintillation vials and counted for  $^3\text{H}$  by liquid scintillation counting.

It is to be understood that the cell lines described herein are merely illustrative of the methods used to evaluate the binding and function of the mammalian receptors of the present invention, and that other suitable cells may be used in the assays described herein.

#### Methods for recording currents in *Xenopus* oocytes

Female *Xenopus laevis* (*Xenopus*-1, Ann Arbor, MI) are anesthetized in 0.2% tricain (3-aminobenzoic acid ethyl ester, Sigma Chemical Corp.) and a portion of ovary is removed using aseptic technique (Quick and Lester, 1994).

Oocytes are defolliculated using 2 mg/ml collagenase (Worthington Biochemical Corp., Freehold, NJ) in a solution containing 87.5 mM NaCl, 2 mM KCl, 2 mM MgCl<sub>2</sub> and 5 mM HEPES, pH 7.5. Oocytes may be injected (Nanject, Drummond Scientific, Broomall, PA) with mammalian mRNA described in this invention. Other oocytes may be injected with a mixture of mammalian mRNA and mRNA encoding the genes for G-protein-activated inward rectifiers (GIRK1 and GIRK4). Genes encoding G-protein inwardly rectifying K<sup>+</sup> (GIRK) channels 1 and 4 (GIRK1 and GIRK4) were obtained by PCR using the published sequences (Kubo et al., 1993; Dascal et al., 1993; Krapivinsky et al., 1995 and 1995b) to derive appropriate 5' and 3' primers. Human heart cDNA was used as template together with the primers

5'-CGCGGATCCATTATGTCTGCACTCCGAAGGAAATTG-3' (Seq. I.D. No. 11) and  
5'-CGCGAATTCCTTATGTGAAGCGATCAGAGTTTCATTTTC -3' (Seq. I.D. No. 12) for GIRK1 and  
5'-GCGGGATCCGCTATGGCTGGTGATTCTAGGAATG-3' (Seq. I.D. No. 13) and  
5'- CCGGAATTCCTCCCTCACACCGAGCCCCTGG-3' (Seq. I.D. No. 14) for GIRK4.

In each primer pair, the upstream primer contained a BamHI site and the downstream primer contained an EcoRI site to facilitate cloning of the PCR product into pCDNA1-Amp (Invitrogen). The transcription template for the mammalian receptor may be similarly obtained. mRNAs are prepared from separate DNA plasmids containing the complete coding regions of the mammalian receptor, GIRK1, and GIRK4. Plasmids are linearized and transcribed using the T7 polymerase ("Message Machine", Ambion). Alternatively, mRNA may be translated from a template generated by PCR, incorporating a T7 promoter and a poly A' tail. Each oocyte receives 2 ng each of GIRK1 and GIRK4 mRNA in combination with 25 ng of mammalian receptor mRNA. After injection of mRNA, oocytes are incubated at

16° on a rotating platform for 3-8 days. Dual electrode voltage clamp ("GeneClamp", Axon Instruments Inc., Foster City, CA) is performed using 3 M KCl-filled glass microelectrodes having resistances of 1-3 Mohms. Unless  
5 otherwise specified, oocytes are voltage clamped at a holding potential of -80 mV. During recordings, oocytes are bathed in continuously flowing (2-5 ml/min) medium containing 96 mM NaCl, 2 mM KCl, 2 mM CaCl<sub>2</sub>, 2 mM MgCl<sub>2</sub>, and 5 mM HEPES, pH 7.5 ("ND96"), or, in the case of  
10 oocytes expressing GIRK1 and GIRK4, elevated K<sup>+</sup> containing 96 mM KCl, 2 mM NaCl, 2 mM CaCl<sub>2</sub>, 2 mM MgCl<sub>2</sub>, and 5 mM HEPES, pH 7.5 ("hK"). Drugs are applied by switching from a series of gravity fed perfusion lines.

15 Heterologous expression of GPCRs in *Xenopus* oocytes has been widely used to determine the identity of signaling pathways activated by agonist stimulation (Gundersen et al., 1983; Takahashi et al., 1987). Activation of the phospholipase C (PLC) pathway is assayed by applying  
20 test compound in ND96 solution to oocytes previously injected with mRNA for the mammalian receptor and observing inward currents at a holding potential of -80 mV. The appearance of currents that reverse at -25 mV and display other properties of the Ca<sup>2+</sup>-activated Cl<sup>-</sup>  
25 (chloride) channel is indicative of mammalian receptor-activation of PLC and release of IP<sub>3</sub> and intracellular Ca<sup>2+</sup>. Such activity is exhibited by GPCRs that couple to G<sub>q</sub>.

30 Measurement of inwardly rectifying K<sup>+</sup> (potassium) channel (GIRK) activity is monitored in oocytes that have been co-injected with mRNAs encoding the mammalian receptor, GIRK1, and GIRK4. The two GIRK gene products co-assemble  
35 to form a G-protein activated potassium channel known to be activated (i.e., stimulated) by a number of GPCRs that couple to G<sub>i</sub> or G<sub>q</sub> (Kubo et al., 1993; Dascal et al., 1993). Oocytes expressing the mammalian receptor plus



the two GIRK subunits are tested for test compound  
responsivity by measuring K<sup>+</sup> currents in elevated K  
solution (hK). Activation of inwardly rectifying  
currents that are sensitive to 300  $\mu$ M Ba<sup>++</sup> signifies the  
5 mammalian receptor coupling to a G<sub>i</sub> or G<sub>o</sub> pathway in the  
oocytes.

#### In vivo methods

10 The effects of administration of human Ob-Re receptor  
protein and related receptors may be evaluated by  
intravenous (i.v.) injection of the receptor followed by  
measurement of food intake in the animal. Measurement of  
food intake may be performed for 3 hours after injection,  
but other protocols may also be used. Saline may be  
15 injected as a control, but it is understood that other  
vehicles may be required as controls for some peptides  
and compounds.

#### Materials

20 Cell culture media and supplements are from Specialty  
Media (Lavallette, NJ). Cell culture plates (150 mm and  
96-well microtiter) are from Corning (Corning, NY). Sf9,  
Sf21, and High Five insect cells, as well as the  
baculovirus transfer plasmid, pBlueBacIII<sup>TM</sup>, are purchased  
25 from Invitrogen (San Diego, CA). TMN-FH insect medium  
complemented with 10% fetal calf serum, and the  
baculovirus DNA, BaculoGold<sup>TM</sup>, is obtained from Pharmingen  
(San Diego, CA). Ex-Cell 400<sup>TM</sup> medium with L-Glutamine  
is purchased from JRH Scientific. Polypropylene 96-well  
30 microtiter plates are from Co-star (Cambridge, MA). All  
radioligands are from New England Nuclear (Boston, MA).

Peptides were either from Bachem California (Torrance,  
CA), Peninsula (Belmont, CA); or were synthesized by  
35 custom order from Chiron Mimotopes Peptide Systems (San  
Diego, CA). Leptin and [<sup>125</sup>I]leptin were provided by  
Novartis. (See also WO96/05309.) Leptin and [<sup>125</sup>I]leptin

are also commercially available from BACHEM and NEN-Dupont, respectively. Bio-Rad Reagent was from Bio-Rad (Hercules, CA). Bovine serum albumin (ultra-fat free, A-7511) was from Sigma (St. Louis, MO). All other materials were reagent grade.

10

15

## Experimental Results

### 3' RACE of Human RNAs for hOb-Re

5 The Ob-R gene consists of multiple exons which can give rise to several splice variants (Lee et al., 1996). The mOb-Re sequence is identical to the mOb-Ra,b,c and d receptors until nucleotide 2389 of the mOb-Rb receptor, and then diverges to encode 9 unique amino acids (Lee et al., 1996). The sequence of the mOb-Ra,b,c and d  
10 receptors are identical until nucleotide 2667 of mOb-Rb, at which point each has an alternative 3' end (Lee et al., 1996). Figure 1 illustrates the likely genomic structure for the 3' end of the mouse Ob-R gene. While two exons in the 5' region common to all splice variants are illustrated, the actual number of these is not  
15 presently known. The human Ob-Rb and Ob-Ra receptors have been cloned and the hOb-R gene appears to have a similar structure to the mouse (Tartaglia et al, 1995; Cioffi et al., 1996). Assuming that the hOb-Re-specific sequence would be located in an analogous location as  
20 found in the mouse, we performed 3'RACE on human cDNAs in order to identify the human Ob-Re splice variant. 3' RACE was performed using several nested primer sets, as illustrated in Table 1. 3' RACE products were sequenced,  
25 identifying hOb-Ra and HuB219.1 in human kidney, heart, skeletal muscle, adipose and lung. hOb-Rb was also identified in kidney. However, 3' sequences homologous to mOb-Re were not identified in any of these tissues.

### Low Stringency PCR for hOb-Re

30 The sequences for the mouse and human Ob-Ra share 82% nucleotide identity. We therefore attempted to use the mOb-Re-specific sequence to amplify the hOb-Re gene. Low stringency PCR was performed on human kidney, liver,  
35 skeletal muscle and heart using a forward primer from a common region of hOb-R (DC4) and a reverse primer from the mouse Ob-Re sequence (BB116). No bands were

amplified in any of these tissues.

#### Identification of Human Ob-Re-Specific Sequence

Figure 1 illustrates the likely genomic structure of the 3' end of the mOb-R gene based on previous findings (Lee et al., 1996). To identify the location of the mOb-Re-specific exon, we amplified mouse genomic DNA using PCR primers from the exons believed to be immediately upstream (BB130) and downstream (BB131) of the mOb-Re-specific exon (Figure 1). Upon sequencing this portion of genomic DNA, it was revealed that the mOb-Re-specific sequence is located immediately downstream of the upstream common exon, with no intervening intron. This new finding suggests that the genomic structure of the mOb-R gene actually contains either two contiguous exons (Figure 2a) or that the Ob-Re-specific sequence is encoded by an unspliced intron (Figure 2b). We next performed a similar experiment on human genomic DNA in order to determine if the hOb-Re-specific sequence is encoded in a similar manner, and to identify the hOb-Re sequence. Human genomic DNA was amplified using PCR primers from the hOb-R exons immediately upstream (DC4) and downstream (BB132) of the analogous exons that flank the mOb-Re-specific sequence. A 2.2 kb product was sequenced and found to be identical to hOb-Rb from DC4 up to nucleotide 2495, after which it diverged completely from any of the published hOb receptors. This novel sequence contained an open reading frame encoding 6 amino acids, and shares 83% nucleotide identity to the mouse Ob-Re-specific sequence (Figure 3). The nucleotide sequence of the complete coding region of human Ob-Re is shown in Figure 4. The deduced amino acid sequence is shown in Figure 5. These new findings suggest that the hOb-R gene contains either two contiguous exons (Figure 6a) or that the hOb-Re-specific sequence is encoded by an unspliced intron (Figure 6b).

#### Localization of Ob-Re in Human Tissues

hOb-Re was originally identified in human genomic DNA. In order to determine if this receptor isoform is expressed in tissues, we performed RT-PCR to identify human tissues that express hOb-Re. hOb-Re was not detected by PCR in cDNA prepared from human hypothalamus, total brain, heart, kidney, skeletal muscle, liver, lung or adipose. To increase the level of detection, we repeated the PCR using as a template products from 3' RACE reactions. However, hOb-Re was not detected by PCR using as a template first PCR products of 3' RACE reactions from human heart, skeletal muscle and adipose. hOb-Re was amplified from the first PCR of a 3' RACE reaction from lung. Using a forward PCR primer corresponding to a region of Ob-Rb two exons upstream from the Ob-Re-specific sequence (BB16), and nested reverse primers from within the hOb-Re-specific sequence (BB138 and BB139), a 2 kb and a 0.26 kb band were amplified from human lung cDNA while only a 2 kb band was amplified from human genomic DNA. DNA sequencing revealed that the 2 kb band contained an intron while the 0.26 kb band contained the sequence for the 3' end of the hOb-Re receptor. This demonstrates that although there was some genomic contamination in the human lung cDNA, this cDNA also expresses the processed Ob-Re message.

#### Expression of hOb-Re in COS-7 Cells

We tested [<sup>125</sup>I]leptin binding using SPA on both the medium and the cells of hOb-Re-transfected COS-7 cells over 1-6 days post-transfection. Binding signal was significantly better for the medium although some level of specific binding was observed on cells also (Figure 7). No binding signal was observed either in the medium or the cells of mock-transfected plates. Binding signal was optimum between 2-3 days post-transfection (Figure 8). The maximum specific binding was 2-fold greater in optitem medium vs. normal DMEM medium. The IC<sub>50</sub> value

obtained for unlabeled leptin displacement of [ $^{125}$ I]leptin for hOb-Re was comparable to that obtained for hOb-Rb using SPA ( $IC_{50}$  10-15 nM; Figure 9).

5 Expression of hOb-Re in Insect Cells

A baculovirus expression system was used to express hOb-Re in SF21 insect cells. Assays were conducted to optimize both the MOI and the time course for binding. An MOI of 1-10 and supernatant collected between 2-5 day post-infection were evaluated (Figure 10). There were no significant differences in binding between the different MOI concentrations. Binding appeared somewhat better 3 days post-infection compared to other time points. Finally, 500 mL of a high titer stock of virus was prepared at an MOI of 0.1 and supernatant was collected 5 days post infection. This viral stock may be used to infect insect cells on a large scale for mass production of hOb-Re protein. A sample of this high titer stock was tested for binding. Unlabeled leptin displaced [ $^{125}$ I]leptin binding to hOb-Re receptor expressed by insect cells with a high affinity ( $IC_{50}$  about 2nM; Figure 11).

Table 1. Primer sets used in 3' RACE experiments

Human Tissue	First PCR Primer Set		Nested PCR Primer Set	
Kidney	AP1	BB75	AP2	BB76
	AP1	BB76	AP2	DC4
	AP1	BB76	AP2	BB87
Liver	AP1	DC17	AP2	DC18
	AP1	DC17	AP2	DC18
	AP1	DC17	AP2	DC4
Skeletal Muscle	AP1	DC17	AP2	DC18
	AP1	DC17	AP2	DC4

Heart	AP1	BB75	AP2	DC4
	AP1	BB76	AP2	DC4
	AP1	DC17	AP2	DC18
	AP1	DC17	AP2	DC4
5 adipose	AP1	DC17	AP2	DC18
Lung	AP1	DC17	AP2	DC18

**Table 2. Primers used:**

- 10 BB75 (nucs 919-944 of hOb-Rb):  
5' CAGGTGAGGGCAAGAGACTGGATGG 3' (Seq. I.D. No. 15).
- BB76 (nucs 2122-2148 of hOb-Rb):  
5' CAAGCACATACTGTTACGGTCTCGCA 3' (Seq. I.D. No. 16).
- BB87 (nucs 2632-2657 of hOb-Rb):  
15 5' CCCAAGAATTGTTCTCGGCACAAGG 3' (Seq. I.D. No. 17).
- BB116 (nucs 2413-2390 of mOb-Re and nucs 2394-2391 of hOb-Rb):  
5' CCATGAAAAGTACAGTACACATACCATGG 3' (Seq. I.D. No. 18).
- 20 BB130 (nucs 2238-2262 of mOb-Rb):  
5' CCTGAGCAGCAGCTGTGTCATCCTT 3' (Seq. I.D. No. 19).
- BB131 (nucs 2513-2488 of mOb-Rb):  
5' GCGTCATTCTGCTGCTTGTCTGATAGC 3' (Seq. I.D. No. 20).
- BB132 (nucs 2438-2413 of hOb-Rb):  
25 5' GGGTAAAGACTGAAGTGGTACTTCTC 3' (Seq. I.D. No. 21).
- BB138 (nucs 2391-2415 of hOb-Re):  
5' CTAAAGTATAGTAACTTACCATGG 3' (Seq. I.D. No. 22).
- BB139 (from 3'UT of hOb-Re):  
30 5' GGATTATATGTATTAGGATGGTAGTATCC 3' (Seq. I.D. No. 23).
- BB157 (from nucs 2372-2395 of hOb-Rb and nucs 2396-2415 of hOb-Re):  
5' TCTGTTAAGAAGTATTATCCATGGTAAGTTTACTATACTTTAG  
TAATGAATGA 3' (Seq. I.D. No. 24).
- 35 BB158 (from nucs 2415-2396 of hOb-Re of hOb-Rb and nucs 2395-2372):

5' AGCTTCATTCACTACTAAAGTATAGTAACTTACCATGGATAT  
AATACTTCTTAAC 3' (Seq. I.D. No. 25).

DC4 (nucs 2218-2243 of hOb-Rb):

5' ATCGTGCAGTCACTCAGTGCTTATCC 3' (Seq. I.D. No. 26).

5 DC16 (nucs 2145-2174 of hOb-Rb):

5' GGCCATCAATTCAATTGGTGCTTCTGTTGC 3' (Seq. I.D. No.  
27).

DC17 (nucs 1874-1902 of hOb-Rb):

10 5' GGAGCAATCCAGCCTACACAGTTGTCATG 3' (Seq. I.D. No.  
28).

DC18 (nucs 2057-2085 of hOb-Rb):

5' CCTGCAATGGAACATGGTCAGAAAGATG 3' (Seq. I.D. No. 29).



References:

- Burns, C.M., Chu, H., Rueter, S.M., Sanders-Bush, E., and R.B. Erneson. (1996) Neuroscience Abstracts 385.9.
- 5 Cheng, Y.C. and Prusoff, W.H. (1973). Relationship between the inhibition constant ( $K_i$ ) and the concentration of inhibitor which causes 50% inhibition ( $IC_{50}$ ) of an enzyme reaction. Biochem. Pharmacol. 22:3099-3108.
- 10 Chu, H., Burns, C., Canton, H., Emeson, R.B., and E. Sanders-Bush. (1996) Neuroscience Abstracts 385.10.
- 15 Cullen, B. (1987) Use of eukaryotic expression technology in the functional analysis of cloned genes. Meth. Enzymol. 152:685-704.
- 20 Cioffi, J.A., Shafer, A.W., Zupanic, T.J., Smithe-Gbur, J., Mikhail, A., Platika, D., and Snodgrass, H.R. (1996). Novel B219/OB receptor isoforms: Possible role of leptin in hematopoiesis and reproduction. Nature Medicine 2:585-589.
- 25 Dascal, N., Schreibmayer, W., Lim, N. F., Wang, W., Chavkin, C., DiMagno, L., Labarca, C., Kieffer, B. L., Gaveriaux-Ruff, C., Trollinger, D., Lester, H. A., Davidson, N. (1993) Proc. Natl. Acad. Sci. USA 90:10235-10239.
- 30 Gundersen, C. B., Miledi, R., Parker, I. (1983) Proc. R. Soc. London Ser. B 219:103-109.
- 35 Krapivinsky, G., Gordon, E. A., Wickman, B., Velimirovic, B., Krapivinsky, L., Clapham, D. E. (1995) Nature 374:135-141.

Kubo, Y., Reuveny, E., Slesinger, P. A., Jan, Y. N. and Jan, L. Y. (1993) *Nature* 364:802-806.

5 Lazareno, S. and Birdsall, N. (1993) *Br. J. Pharmacol.* 109:1120-1127.

10 Lee, G.-H., Proenca, R., Montez, J.M., Carroll, K.M., Dirvishzadeh, J.G, Lee, J.I, and Friedman, J.M. (1996). Abnormal splicing of the leptin receptor in *diabetic* mice. Nature 379:632-635.

Quick, M. W. and Lester, H. A. (1994) *Meth. Neurosci.* 19:261-279.

15 Takahashi, T., Neher, E., and Sakmann, B. (1987) *Proc. Natl. Acad. Sci. USA* 84:5063-6067.

20 Tartaglia, L.A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., Richards, G.J., Campfield, L.A., Clark, F.T., Deeds, J., Muir, C, Sanker, S., Moriarty, A., Moore, K.J., Smutko, J.S., Mays, G.G., Woolf, E.A., Monroe, C.A., and Tepper, R.I. (1995). Identification and expression cloning of a leptin receptor, OB-R. Cell 83:1263-1271.

25 Tian, W. N., Duzic, E., Lanier, S., and Deth, R. C. (1994) *Mol. Pharmacol.* 45:524-531.

30

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Borowsky, Beth
- (ii) TITLE OF INVENTION: DNA ENCODING A HUMAN Ob RECEPTOR (hOb-Re) AND USES THEREOF
- (iii) NUMBER OF SEQUENCES: 29
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Cooper & Dunham LLP
  - (B) STREET: 1185 Avenue of the Americas
  - (C) CITY: New York
  - (D) STATE: New York
  - (E) COUNTRY: USA
  - (F) ZIP: 10036
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: White, John P
  - (B) REGISTRATION NUMBER: 28,678
  - (C) REFERENCE/DOCKET NUMBER: 1795-53801/JPW/KDB
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 212 278 0400
  - (B) TELEFAX: 212 291 0525

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 54 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (ix) FEATURE:
  - (A) NAME/KEY: CDS
  - (B) LOCATION: 1..54
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAT GTT AAA AAG TTT CAC ATC CAC GGT ATG TGT ACT GTA CTT TTC ATG  
Asn Val Lys Lys Phe His Ile His Gly Met Cys Thr Val Leu Phe Met  
1 5 10 15

48

GAT TAG

54

Asp \*

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Asn	Val	Lys	Lys	Phe	His	Ile	His	Gly	Met	Cys	Thr	Val	Leu	Phe	Met
1				5					10					15	

Asp \*

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 45 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:
  - (A) NAME/KEY: CDS
  - (B) LOCATION: 1..45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TCT	GTT	AAG	AAG	TAT	TAT	ATC	CAT	GGT	AAG	TTT	ACT	ATA	CTT	TAG	45
Ser	Val	Lys	Lys	Tyr	Tyr	Ile	His	Gly	Lys	Phe	Thr	Ile	Leu	*	
1				5					10					15	

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ser	Val	Lys	Lys	Tyr	Tyr	Ile	His	Gly	Lys	Phe	Thr	Ile	Leu	*
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:  
(A) NAME/KEY: CDS  
(B) LOCATION: 1..27

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GGT ATG TGT ACT GTA CTT TTC ATG GAT  
Gly Met Cys Thr Val Leu Phe Met Asp  
1 5

27

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 9 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Gly Met Cys Thr Val Leu Phe Met Asp  
1 5

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:  
(A) NAME/KEY: CDS  
(B) LOCATION: 1..18

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GGT AAG TTT ACT ATA CTT  
Gly Lys Phe Thr Ile Leu  
10 15

18

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Gly Lys Phe Thr Ile Leu  
1 5

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 2415 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

- (ix) FEATURE:  
(A) NAME/KEY: CDS  
(B) LOCATION: 1..2415

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATG ATT TGT CAA AAA TTC TGT GTG GTT TTG TTA CAT TGG GAA TTT ATT	48
Met Ile Cys Gln Lys Phe Cys Val Val Leu Leu His Trp Glu Phe Ile	
1 5 10 15	
TAT GTG ATA ACT GCG TTT AAC TTG TCA TAT CCA ATT ACT CCT TGG AGA	96
Tyr Val Ile Thr Ala Phe Asn Leu Ser Tyr Pro Ile Thr Pro Trp Arg	
20 25 30	
TTT AAG TTG TCT TGC ATG CCA CCA AAT TCA ACC TAT GAC TAC TTC CTT	144
Phe Lys Leu Ser Cys Met Pro Pro Asn Ser Thr Tyr Asp Tyr Phe Leu	
35 40 45	
TTG CCT GCT GGA CTC TCA AAG AAT ACT TCA AAT TCG AAT GGA CAT TAT	192
Leu Pro Ala Gly Leu Ser Lys Asn Thr Ser Asn Ser Asn Gly His Tyr	
50 55 60	
GAG ACA GCT GTT GAA CCT AAG TTT AAT TCA AGT GGT ACT CAC TTT TCT	240
Glu Thr Ala Val Glu Pro Lys Phe Asn Ser Ser Gly Thr His Phe Ser	
65 70 75 80	
AAC TTA TCC AAA ACA ACT TTC CAC TGT TGC TTT CGG AGT GAG CAA GAT	288
Asn Leu Ser Lys Thr Thr Phe His Cys Cys Phe Arg Ser Glu Gln Asp	
85 90 95	
AGA AAC TGC TCC TTA TGT GCA GAC AAC ATT GAA GGA AAG ACA TTT GTT	336
Arg Asn Cys Ser Leu Cys Ala Asp Asn Ile Glu Gly Lys Thr Phe Val	
100 105 110	
TCA ACA GTA AAT TCT TTA GTT TTT CAA CAA ATA GAT GCA AAC TGG AAC	384
Ser Thr Val Asn Ser Leu Val Phe Gln Gln Ile Asp Ala Asn Trp Asn	
115 120 125	
ATA CAG TGC TGG CTA AAA GGA GAC TTA AAA TTA TTC ATC TGT TAT GTC	432
Ile Gln Cys Trp Leu Lys Gly Asp Leu Lys Leu Phe Ile Cys Tyr Val	
130 135 140	
GAG TCA TTA TTT AAG AAT CTA TTC AGG AAT TAT AAC TAT AAG GTC CAT	480

Glu 145	Ser	Leu	Phe	Lys	Asn 150	Leu	Phe	Arg	Asn 155	Tyr	Asn	Tyr	Lys	Val	His 160	
CTT Leu	TTA Leu	TAT Tyr	GTT Val	CTG Leu 165	CCT Pro	GAA Glu	GTG Val	TTA Leu	GAA Glu 170	GAT Asp	TCA Ser	CCT Pro	CTG Leu	GTT Val 175	CCC Pro	528
CAA Gln	AAA Lys	GGC Gly	AGT Ser 180	TTT Phe	CAG Gln	ATG Met	GTT Val	CAC His 185	TGC Cys	AAT Asn	TGC Cys	AGT Ser	GTT Val 190	CAT His	GAA Glu	576
TGT Cys	TGT Cys	GAA Cys 195	TGT Cys	CTT Leu	GTG Val	CCT Pro	GTG Val 200	CCA Pro	ACA Thr	GCC Ala	AAA Lys	CTC Leu 205	AAC Asn	GAC Asp	ACT Thr	624
CTC Leu	CTT Leu 210	ATG Met	TGT Cys	TTG Leu	AAA Lys	ATC Ile 215	ACA Thr	TCT Ser	GGT Gly	GGA Gly	GTA Val 220	ATT Ile	TTC Phe	CAG Gln	TCA Ser	672
CCT Pro 225	CTA Leu	ATG Met	TCA Ser	GTT Val	CAG Gln 230	CCC Pro	ATA Ile	AAT Asn	ATG Met	GTG Val 235	AAG Lys	CCT Pro	GAT Asp	CCA Pro	CCA Pro 240	720
TTA Leu	GGT Gly	TTG Leu	CAT His	ATG Met 245	GAA Glu	ATC Ile	ACA Thr	GAT Asp	GAT Asp 250	GGT Gly	AAT Asn	TTA Leu	AAG Lys	ATT Ile 255	TCT Ser	768
TGG Trp	TCC Ser	AGC Ser	CCA Pro 260	CCA Pro	TTG Leu	GTA Val	CCA Pro	TTT Phe 265	CCA Pro	CTT Leu	CAA Gln	TAT Tyr	CAA Gln 270	GTG Val	AAA Lys	816
TAT Tyr	TCA Ser	GAG Glu 275	AAT Asn	TCT Ser	ACA Thr	ACA Thr	GTT Val 280	ATC Ile	AGA Arg	GAA Glu	GCT Ala	GAC Asp 285	AAG Lys	ATT Ile	GTC Val	864
TCA Ser	GCT Ala 290	ACA Thr	TCC Ser	CTG Leu	CTA Leu	GTA Val 295	GAC Asp	AGT Ser	ATA Ile	CTT Leu	CCT Pro 300	GGG Pro	TCT Gly	TCG Ser	TAT Tyr	912
GAG Glu 305	GTT Val	CAG Gln	GTG Val	AGG Arg	GGC Gly 310	AAG Lys	AGA Arg	CTG Leu	GAT Asp 315	GGC Gly	CCA Pro	GGA Pro	ATC Gly	TGG Ile	AGT Ser 320	960
GAC Asp	TGG Trp	AGT Ser	ACT Thr	CCT Pro 325	CGT Arg	GTC Val	TTT Phe	ACC Thr	ACA Thr 330	CAA Gln	GAT Asp	GTC Val	ATA Ile	TAC Ile 335	TTT Phe	1008
CCA Pro	CCT Pro	AAA Lys	ATT Ile 340	CTG Leu	ACA Thr	AGT Ser	GTT Val	GGG Gly 345	TCT Ser	AAT Asn	GTT Val	TCT Ser	TTT Phe 350	CAC His	TGC Cys	1056
ATC Ile	TAT Tyr	AAG Lys 355	AAG Lys	GAA Asn	AAC Lys	AAG Lys 360	ATT Ile	GTT Val	CCC Pro	TCA Leu	AAA Ser	GAG Lys 365	ATT Glu	GTT Ile	TGG Val	1104
TGG Trp	ATG Met	AAT Asn 370	TTA Leu	GCT Ala	GAG Glu	AAA Lys 375	ATT Ile	CCT Pro	CAA Gln	AGC Ser	CAG Gln	TAT Tyr	GAT Asp	GTT Val	GTG Val	1152
AGT Ser 385	GAT Asp	CAT His	GTT Val	AGC Ser	AAA Lys 390	GTT Val	ACT Thr	TTT Phe	TTC Phe	AAT Asn 395	CTG Leu	AAT Asn	GAA Glu	ACC Thr	AAA Lys 400	1200

CCT Pro	CGA Arg	GGA Gly	AAG Lys	TTT Phe 405	ACC Thr	TAT Tyr	GAT Asp	GCA Ala	GTG Val 410	TAC Tyr	TGC Cys	TGC Cys	AAT Asn	GAA Glu 415	CAT His	1248
GAA Glu	TGC Cys	CAT His	CAT His 420	CGC Arg	TAT Tyr	GCT Ala	GAA Glu	TTA Leu 425	TAT Tyr	GTG Val	ATT Ile	GAT Asp	GTC Val 430	AAT Asn	ATC Ile	1296
AAT Asn	ATC Ile	TCA Ser 435	TGT Cys	GAA Glu	ACT Thr	GAT Asp	GGG Gly 440	TAC Tyr	TTA Leu	ACT Thr	AAA Lys 445	ATG Met	ACT Thr	TGC Cys	AGA Arg	1344
TGG Trp	TCA Ser	ACC Thr 450	AGT Ser	ACA Thr	ATC Ile	CAG Gln 455	TCA Ser	CTT Leu	GCG Ala	GAA Glu	AGC Glu 460	ACT Thr	TTG Leu	CAA Gln	TTG Leu	1392
AGG Arg	TAT Tyr	CAT His 465	AGG Arg	AGC Ser	AGC Ser 470	CTT Leu	TAC Tyr	TGT Cys	TCT Ser	GAT Ser 475	ATT Ile	CCA Pro	TCT Ser	ATT Ile	CAT His 480	1440
CCC Pro	ATA Ile	TCT Ser 485	GAG Glu	CCC Gln 485	AAA Lys	GAT Asp	TGC Cys	TAT Tyr	TTG Leu 490	CAG Gln	AGT Ser	GAT Asp	GGT Gly 495	TTT Phe 495	TAT Tyr	1488
GAA Glu	TGC Cys	ATT Ile 500	TTC Phe	CAG Gln 500	CCA Pro	ATC Ile	TTC Phe	CTA Leu 505	TTA Leu	TCT Ser	GGC Gly	TAC Tyr	ACA Thr 510	ATG Met	TGG Trp	1536
ATT Ile	AGG Arg	ATC Ile 515	AAT Asn	CAC His	TCT Ser	CTA Leu	GGT Gly 520	TCA Ser	CTT Leu	GAC Asp	TCT Ser	CCA Pro 525	CCA Pro	ACA Thr	TGT Cys	1584
GTC Val	CTT Leu 530	CCT Pro	GAT Asp	TCT Ser	GTG Val 535	GTG Val	AAG Lys	CCA Pro	CTG Leu	CCT Pro	CCA Pro 540	TCC Ser	AGT Ser	GTG Val	AAA Lys	1632
GCA Ala	GAA Glu 545	ATT Ile	ACT Thr	ATA Ile 550	AAC Asn	ATT Ile	GGA Gly 555	TTA Leu	TTG Leu	AAA Lys 555	ATA Ile	TCT Ser	TGG Trp	GAA Glu 560	AAG Lys 560	1680
CCA Pro	GTC Val	TTT Phe	CCA Pro	GAG Glu 565	AAT Asn	AAC Asn	CTT Leu	CAA Gln	TTC Phe 570	CAG Gln	ATT Ile	CGC Arg	TAT Tyr	GGT Gly 575	TTA Leu	1728
AGT Ser	GGA Gly	AAA Lys 580	GAA Glu	GTA Val	CAA Gln	TGG Trp	AAG Lys	ATG Met 585	TAT Tyr	GAG Glu	GTT Val	TAT Tyr	GAT Asp 590	GCA Ala	AAA Lys	1776
TCA Ser	AAA Lys 595	TCT Val	GTC Val	AGT Ser	CTC Leu	CCA Pro	GTT Val 600	CCA Pro	GAC Asp	TTG Leu	TGT Cys	GCA Ala 605	GTC Val	TAT Tyr	GCT Ala	1824
GTT Val	CAG Gln 610	GTG Val	CGC Arg	TGT Cys	AAG Lys	AGG Arg 615	CTA Leu	GAT Asp	GGA Gly	CTG Leu 620	GGA Gly	TAT Tyr	TGG Trp	AGT Ser	AAT Asn	1872
TGG Trp 625	AGC Ser	AAT Asn	CCA Pro	GCC Ala	TAC Tyr 630	ACA Thr	GTT Val	GTC Val	ATG Met	GAT Asp 635	ATA Ile	AAA Lys	GTT Val	CCT Pro	ATG Met 640	1920
AGA Arg	GGA Gly	CCT Pro	GAA Glu	TTT Phe	TGG Trp	AGA Arg	ATA Ile	ATT Ile	AAT Asn	GGA Gly	GAT Asp	ACT Thr	ATG Met	AAA Lys	AAG Lys	1968



645										650										655											
GAG Glu	AAA Lys	AAT Asn	GTC Val 660	ACT Thr	TTA Leu	CTT Leu	TGG Trp	AAG Lys 665	CCC Pro	CTG Leu	ATG Met	AAA Lys	AAT Asn 670	GAC Asp	TCA Ser																2016
TTG Leu	TGC Cys	AGT Ser 675	GTT Val	CAG Gln	AGA Arg	TAT Tyr	GTG Val 680	ATA Ile	AAC Asn	CAT His	CAT His	ACT Thr 685	TCC Ser	TGC Cys	AAT Asn																2064
GGA Gly	ACA Thr 690	TGG Trp	TCA Ser	GAA Glu	GAT Asp	GTG Val 695	GGA Gly	AAT Asn	CAC His	ACG Thr 700	AAA Lys 700	TTC Phe	ACT Thr	TTC Phe	CTG Leu																2112
TGG Trp 705	ACA Thr	GAG Glu	CAA Gln	GCA Ala	CAT His 710	ACT Thr	GTT Val	ACG Thr	GTT Val	CTG Val 715	GCC Ala	ATC Ile	AAT Asn	TCA Ser	ATT Ile 720																2160
GGT Gly	GCT Ala	TCT Ser	GTT Val	GCA Ala 725	AAT Asn	TTT Phe	AAT Asn	TTA Leu	ACC Thr 730	TTT Phe	TCA Ser	TGG Trp	CCT Pro	ATG Met 735	AGC Ser																2208
AAA Lys	GTA Val	AAT Asn	ATC Ile 740	GTG Val	CAG Gln	TCA Ser	CTC Leu	AGT Ser 745	GCT Ala	TAT Tyr	CCT Pro	TTA Leu	AAC Asn 750	AGC Ser	AGT Ser																2256
TGT Cys	GTG Val	ATT Ile 755	GTT Val	TCC Ser	TGG Trp	ATA Ile 760	CTA Leu	TCA Ser	CCC Pro	AGT Ser	GAT Asp	TAC Tyr 765	AAG Gly	CTA Leu	ATG Met																2304
TAT Tyr	TTT Phe 770	ATT Ile	ATT Ile	GAG Glu	TGG Trp	AAA Lys 775	AAT Asn	CTT Leu	AAT Asn	GAA Glu 780	GAT Asp	GGT Gly 780	GAA Glu	ATA Ile	AAA Lys																2352
TGG Trp 785	CTT Leu	AGA Arg	ATC Ile	TCT Ser	TCA Ser 790	TCT Ser	GTT Val	AAG Lys	AAG Lys	TAT Tyr 795	TAT Tyr	ATC Ile	CAT His	GGT Gly	AAG Lys 800																2400
TTT Phe	ACT Thr	ATA Ile	CTT Leu	TAG * 805																											2415

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 805 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Ile Cys Gln Lys Phe Cys Val Val Leu Leu His Trp Glu Phe Ile  
 1 5 10 15  
 Tyr Val Ile Thr Ala Phe Asn Leu Ser Tyr Pro Ile Thr Pro Trp Arg  
 20 25 30  
 Phe Lys Leu Ser Cys Met Pro Pro Asn Ser Thr Tyr Asp Tyr Phe Leu  
 35 40 45

Leu Pro Ala Gly Leu Ser Lys Asn Thr Ser Asn Ser Asn Gly His Tyr  
 50 55 60  
 Glu Thr Ala Val Glu Pro Lys Phe Asn Ser Ser Gly Thr His Phe Ser  
 65 70 75 80  
 Asn Leu Ser Lys Thr Thr Phe His Cys Cys Phe Arg Ser Glu Gln Asp  
 85 90 95  
 Arg Asn Cys Ser Leu Cys Ala Asp Asn Ile Glu Gly Lys Thr Phe Val  
 100 105 110  
 Ser Thr Val Asn Ser Leu Val Phe Gln Gln Ile Asp Ala Asn Trp Asn  
 115 120 125  
 Ile Gln Cys Trp Leu Lys Gly Asp Leu Lys Leu Phe Ile Cys Tyr Val  
 130 135 140  
 Glu Ser Leu Phe Lys Asn Leu Phe Arg Asn Tyr Asn Tyr Lys Val His  
 145 150 155 160  
 Leu Leu Tyr Val Leu Pro Glu Val Leu Glu Asp Ser Pro Leu Val Pro  
 165 170 175  
 Gln Lys Gly Ser Phe Gln Met Val His Cys Asn Cys Ser Val His Glu  
 180 185 190  
 Cys Cys Glu Cys Leu Val Pro Val Pro Thr Ala Lys Leu Asn Asp Thr  
 195 200 205  
 Leu Leu Met Cys Leu Lys Ile Thr Ser Gly Gly Val Ile Phe Gln Ser  
 210 215 220  
 Pro Leu Met Ser Val Gln Pro Ile Asn Met Val Lys Pro Asp Pro Pro  
 225 230 235 240  
 Leu Gly Leu His Met Glu Ile Thr Asp Asp Gly Asn Leu Lys Ile Ser  
 245 250 255  
 Trp Ser Ser Pro Pro Leu Val Pro Phe Pro Leu Gln Tyr Gln Val Lys  
 260 265 270  
 Tyr Ser Glu Asn Ser Thr Thr Val Ile Arg Glu Ala Asp Lys Ile Val  
 275 280 285  
 Ser Ala Thr Ser Leu Leu Val Asp Ser Ile Leu Pro Gly Ser Ser Tyr  
 290 295 300  
 Glu Val Gln Val Arg Gly Lys Arg Leu Asp Gly Pro Gly Ile Trp Ser  
 305 310 315 320  
 Asp Trp Ser Thr Pro Arg Val Phe Thr Thr Gln Asp Val Ile Tyr Phe  
 325 330 335  
 Pro Pro Lys Ile Leu Thr Ser Val Gly Ser Asn Val Ser Phe His Cys  
 340 345 350  
 Ile Tyr Lys Lys Glu Asn Lys Ile Val Pro Ser Lys Glu Ile Val Trp  
 355 360 365  
 Trp Met Asn Leu Ala Glu Lys Ile Pro Gln Ser Gln Tyr Asp Val Val  
 370 375 380

Ser	Asp	His	Val	Ser	Lys	Val	Thr	Phe	Phe	Asn	Leu	Asn	Glu	Thr	Lys
385				390					395						400
Pro	Arg	Gly	Lys	Phe	Thr	Tyr	Asp	Ala	Val	Tyr	Cys	Cys	Asn	Glu	His
				405				410						415	
Glu	Cys	His	His	Arg	Tyr	Ala	Glu	Leu	Tyr	Val	Ile	Asp	Val	Asn	Ile
			420					425					430		
Asn	Ile	Ser	Cys	Glu	Thr	Asp	Gly	Tyr	Leu	Thr	Lys	Met	Thr	Cys	Arg
		435					440					445			
Trp	Ser	Thr	Ser	Thr	Ile	Gln	Ser	Leu	Ala	Glu	Ser	Thr	Leu	Gln	Leu
		450				455					460				
Arg	Tyr	His	Arg	Ser	Ser	Leu	Tyr	Cys	Ser	Asp	Ile	Pro	Ser	Ile	His
465					470					475					480
Pro	Ile	Ser	Glu	Pro	Lys	Asp	Cys	Tyr	Leu	Gln	Ser	Asp	Gly	Thr	Tyr
				485					490					495	
Glu	Cys	Ile	Phe	Gln	Pro	Ile	Phe	Leu	Leu	Ser	Gly	Tyr	Thr	Met	Trp
			500					505					510		
Ile	Arg	Ile	Asn	His	Ser	Leu	Gly	Ser	Leu	Asp	Ser	Pro	Pro	Thr	Cys
		515					520					525			
Val	Leu	Pro	Asp	Ser	Val	Val	Lys	Pro	Leu	Pro	Pro	Ser	Ser	Val	Lys
					535						540				
Ala	Glu	Ile	Thr	Ile	Asn	Ile	Gly	Leu	Leu	Lys	Ile	Ser	Trp	Glu	Lys
545					550					555					560
Pro	Val	Phe	Pro	Glu	Asn	Asn	Leu	Gln	Phe	Gln	Ile	Arg	Tyr	Gly	Leu
				565					570					575	
Ser	Gly	Lys	Glu	Val	Gln	Trp	Lys	Met	Tyr	Glu	Val	Tyr	Asp	Ala	Lys
			580					585					590		
Ser	Lys	Ser	Val	Ser	Leu	Pro	Val	Pro	Asp	Leu	Cys	Ala	Val	Tyr	Ala
		595				600						605			
Val	Gln	Val	Arg	Cys	Lys	Arg	Leu	Asp	Gly	Leu	Gly	Tyr	Trp	Ser	Asn
		610				615					620				
Trp	Ser	Asn	Pro	Ala	Tyr	Thr	Val	Val	Met	Asp	Ile	Lys	Val	Pro	Met
625				630						635				640	
Arg	Gly	Pro	Glu	Phe	Trp	Arg	Ile	Ile	Asn	Gly	Asp	Thr	Met	Lys	Lys
				645					650					655	
Glu	Lys	Asn	Val	Thr	Leu	Leu	Trp	Lys	Pro	Leu	Met	Lys	Asn	Asp	Ser
			660					665					670		
Leu	Cys	Ser	Val	Gln	Arg	Tyr	Val	Ile	Asn	His	His	Thr	Ser	Cys	Asn
		675					680					685			
Gly	Thr	Trp	Ser	Glu	Asp	Val	Gly	Asn	His	Thr	Lys	Phe	Thr	Phe	Leu
		690				695					700				
Trp	Thr	Glu	Gln	Ala	His	Thr	Val	Thr	Val	Leu	Ala	Ile	Asn	Ser	Ile
705				710						715					720

Gly	Ala	Ser	Val	Ala	Asn	Phe	Asn	Leu	Thr	Phe	Ser	Trp	Pro	Met	Ser
				725					730					735	
Lys	Val	Asn	Ile	Val	Gln	Ser	Leu	Ser	Ala	Tyr	Pro	Leu	Asn	Ser	Ser
			740					745					750		
Cys	Val	Ile	Val	Ser	Trp	Ile	Leu	Ser	Pro	Ser	Asp	Tyr	Lys	Leu	Met
		755					760					765			
Tyr	Phe	Ile	Ile	Glu	Trp	Lys	Asn	Leu	Asn	Glu	Asp	Gly	Glu	Ile	Lys
	770					775					780				
Trp	Leu	Arg	Ile	Ser	Ser	Ser	Val	Lys	Lys	Tyr	Tyr	Ile	His	Gly	Lys
785					790					795					800
Phe	Thr	Ile	Leu	*											
				805											

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 37 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CGCGGATCCA TTATGTCCTGC ACTCCGAAGG AAATTTG

37

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 38 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CGCGAATTC TATGTGAAGC GATCAGAGTT CATTITTC

38

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 34 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GCGGGATCCG CTATGGCTGG TGATTC TAGG AATG

34

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CCGGAATTCC CCTCACACCG AGCCCCCTGG

29

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CAGGTGAGGG GCAAGAGACT GGATGG

26

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CAAGCACATA CTGTTACGGT TCTGGCA

27

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CCCAAGAATT GTTCCTGGGC ACAAGG

26

(2) INFORMATION FOR SEQ ID NO:18:

- (1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CCATGAAAAG TACAGTACAC ATACCATGG

29

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 25 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CCTGAGCAGC AGCTGTGTCA TCCTT

25

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GCGTCATTCT GCTGCTTGTC GATAGC

26

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GGGTAAAGAC TGAAGTGGTA CTTCTC

26

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CTAAAGTATA GTAAACTTAC CATGG

25

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 29 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GGATTATATG TATTAGGATG GTAGTATCC

29

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 55 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

TCTGTTAAGA AGTATTATAT CCATGGTAAG TTTACTATAC TTTAGTAATG AATGA

55

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 56 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AGCTTCATTC ATTACTAAG TATAGTAAAC TTACCATGGA TATAATACTT CTTAAC

56

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

ATCGTGCACT CACTCAGTGC TTATCC 26

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GGCCATCAAT TCAATTGGTG CTTCGTGTC 30

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GGAGCAATCC AGCCTACACA GTTGTCTATG 29

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CCTGCAATGG AACATGGTCA GAAGATG 27



What is claimed is:

1. An isolated nucleic acid which encodes a polypeptide comprising the amino acid sequence shown in Figure 5 (Seq. I.D. No. 10) or a polypeptide having a sequence which varies therefrom by no more than 15 amino acids, such amino acid variations not involving amino acid positions 799-804 and not changing the functional properties of the polypeptide.
2. The nucleic acid of claim 1 encoding a polypeptide having the amino acid sequence shown in Figure 5 (Seq. I.D. No. 10).
3. The nucleic acid of claim 1, wherein the nucleic acid is DNA.
4. The DNA of claim 3, wherein the DNA is cDNA.
5. The DNA of claim 3, wherein the DNA is genomic DNA.
6. The nucleic acid of claim 1, wherein the nucleic acid is RNA.
7. A nucleic acid which comprises the nucleic acid of claim 1 linked to a nucleic acid encoding a flag epitope.
8. A nucleic acid which comprises the nucleic acid of claim 1 linked to a nucleic acid encoding a polypeptide corresponding to an artificial transmembrane region of a receptor which is not an Ob receptor.
9. A nucleic acid which comprises the nucleic acid of claim 8 linked to nucleic acid encoding a

polypeptide corresponding to an artificial intracellular domain of a receptor which is not an Ob receptor.

- 5      10. A purified polypeptide encoded by the nucleic acid of claim 1,2, or 7.
11. A purified polypeptide encoded by the nucleic acid of claim 8.
- 10      12. A purified polypeptide encoded by the nucleic acid of claim 9.
13. A vector comprising the nucleic acid of claim 1.
- 15      14. A vector of claim 13 adapted for expression in a bacterial cell which comprises the regulatory elements necessary for expression of the nucleic acid in the bacterial cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.
- 20      15. A vector of claim 13 adapted for expression in a yeast cell which comprises the regulatory elements necessary for expression of the nucleic acid in the yeast cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.
- 25      16. A vector of claim 13 adapted for expression in an insect cell which comprises the regulatory elements necessary for expression of the nucleic acid in the insect cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.
- 30      17. A baculovirus vector of claim 16.
- 35

18. The baculovirus vector of claim 17 designated Bac-BO45 (ATCC Accession No. VR-2574).
- 5 19. A vector of claim 13 adapted for expression in an amphibian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the amphibian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.
- 10 20. A vector of claim 13 adapted for expression in a mammalian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the mammalian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.
- 15 21. A plasmid vector of claim 13.
- 20 22. A plasmid vector of claim 21 adapted for expression in a mammalian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the mammalian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.
- 25 23. The plasmid vector of claim 22 designated BO-25 (ATCC Accession No. 209036).
- 30 24. A vector comprising the nucleic acid of claim 8 or 9.
- 35 25. A vector of claim 24 adapted for expression in a bacterial cell which comprises the regulatory elements necessary for expression of the nucleic acid in the bacterial cell operatively linked to the nucleic acid encoding the polypeptide so as to

permit expression thereof.

- 5 26. A vector of claim 24 adapted for expression in a yeast cell which comprises the regulatory elements necessary for expression of the nucleic acid in the yeast cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.
- 10 27. A vector of claim 24 adapted for expression in an insect cell which comprises the regulatory elements necessary for expression of the nucleic acid in the insect cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.
- 15 28. A baculovirus vector of claim 27.
- 20 29. A vector of claim 24 adapted for expression in an amphibian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the amphibian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.
- 25 30. A vector of claim 24 adapted for expression in a mammalian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the mammalian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.
- 30 31. A plasmid vector of claim 24.
- 35 32. A plasmid vector of claim 31 adapted for expression in a mammalian cell which comprises the regulatory elements necessary for expression of the nucleic

acid in the mammalian cell operatively linked to the nucleic acid encoding the polypeptide so as to permit expression thereof.

- 5      33. A cell comprising the vector of claim 13.
34. A cell of claim 33, wherein the cell is a non-mammalian cell.
- 10     35. A cell of claim 34, wherein the non-mammalian cell is a *Xenopus* oocyte cell or a *Xenopus* melanophore cell.
- 15     36. A cell of claim 33, wherein the cell is a mammalian cell.
37. A mammalian cell of claim 36, wherein the cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell, an LM(tk-) cell or a CHO cell.
- 20     38. An insect cell comprising the vector of claim 17.
39. An insect cell of claim 38, wherein the insect cell is an Sf9 cell, an Sf21 cell or a HighFive cell.
- 25     40. A cell comprising the vector of claim 24.
41. A cell of claim 40, wherein the cell is a non-mammalian cell.
- 30     42. A cell of claim 41, wherein the non-mammalian cell is a *Xenopus* oocyte cell or a *Xenopus* melanophore cell.
- 35     43. A cell of claim 40, wherein the cell is a mammalian cell.

44. A mammalian cell of claim 43, wherein the cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell, an LM(tk-) cell or a CHO cell.
- 5 45. An insect cell comprising the vector of claim 28.
46. An insect cell of claim 45, wherein the insect cell is an Sf9 cell, an Sf21 cell or a HighFive cell.
- 10 47. A membrane preparation isolated from the cell of claim 40.
48. A membrane preparation isolated from the cell of claim 45.
- 15 49. A nucleic acid probe comprising at least 15 nucleotides, which probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence from nucleotide number 2395 through nucleotide number 2412 of Figure 4 (Seq. I.D. No. 9) or (b) a reverse complement thereof.
- 20 50. The nucleic acid probe of claim 49, wherein the nucleotides are deoxyribonucleotides.
- 25 51. The nucleic acid probe of claim 49, wherein the nucleotides are ribonucleotides.
- 30 52. An antisense oligonucleotide having a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence from nucleotide number 2395 through nucleotide number 2412 of Figure 4 (Seq. I.D. No. 9) or (b) a reverse complement thereof.
- 35 53. An antisense oligonucleotide of claim 52 capable of specifically hybridizing to mRNA, so as to prevent

translation of mRNA.

54. An antisense oligonucleotide of claim 52 capable of specifically hybridizing to genomic DNA.
- 5
55. An antisense oligonucleotide of claim 52, wherein the oligonucleotide comprises chemically modified nucleotides or nucleotide analogues.
- 10
56. An antibody capable of specifically binding to the polypeptide containing at least a unique sequence corresponding to a sequence present within the amino acid sequence from amino acid number 799 through amino acid number 804 of Figure 5 (Seq. I.D. No. 10).
- 15
57. An antibody capable of competitively inhibiting the binding of the antibody of claim 56 to the polypeptide to which it specifically binds.
- 20
58. An antibody of claim 56, wherein the antibody is a monoclonal antibody.
59. A pharmaceutical composition comprising an amount of the oligonucleotide of claim 52 effective to reduce expression of a polypeptide and a pharmaceutically acceptable carrier.
- 25
60. A pharmaceutical composition of claim 59, wherein the oligonucleotide is coupled to a substance which inactivates mRNA.
- 30
61. A pharmaceutical composition of claim 60, wherein the substance which inactivates mRNA is a ribozyme.
- 35
62. A pharmaceutical composition of claim 61, wherein the pharmaceutically acceptable carrier comprises a

structure which binds to a receptor on a cell capable of being taken up by the cells after binding to the structure.

- 5      63. A pharmaceutical composition of claim 62, wherein the pharmaceutically acceptable carrier is capable of binding to a receptor which is specific for a selected cell type.
- 10      64. A pharmaceutical composition which comprises an amount of the antibody of claim 56 effective to block binding of a ligand to the polypeptide and a pharmaceutically acceptable carrier.
- 15      65. A transgenic nonhuman mammal expressing a nucleic acid of any one of claims 1, 2, 7, 8 or 9.
- 20      66. A transgenic nonhuman mammal comprising a homologous recombination knockout of a polypeptide expressed by a nucleic acid of any one of claims 1, 2, 7, 8 or 9.
- 25      67. A transgenic nonhuman mammal whose genome comprises antisense DNA complementary to a nucleic acid of any one of claims 1, 2, 7, 8 or 9 so placed as to be transcribed into antisense mRNA which is complementary to mRNA encoding a polypeptide and which hybridizes to mRNA encoding a polypeptide, thereby reducing its translation.
- 30      68. The transgenic nonhuman mammal of claim 65, wherein the nucleic acid additionally comprises an inducible promoter.
- 35      69. The transgenic nonhuman mammal of claim 65, wherein the nucleic acid additionally comprises tissue specific regulatory elements.



70. A transgenic nonhuman mammal of claim 65, wherein the transgenic nonhuman mammal is a mouse.
- 5 71. A process for identifying a chemical compound which specifically binds to a polypeptide of claim 10, which comprises contacting the polypeptide with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the polypeptide.
- 10 72. The process of claim 71, wherein the specific binding of the compound to the polypeptide is detected by means of an antibody which binds to the polypeptide.
- 15 73. The process of claim 71, wherein the specific binding of the compound to the polypeptide is detected by a scintillation proximity assay.
- 20 74. The process of claim 71, wherein the polypeptide has substantially the same amino acid sequence as that shown in Figure 5.
- 25 75. The process of claim 71, wherein the compound is not previously known to bind to the polypeptide.
76. A compound determined by the process of claim 71.
- 30 77. A pharmaceutical composition which comprises an effective amount of a compound determined by the process of claim 71 and a pharmaceutically acceptable carrier.
- 35 78. A process involving competitive binding for identifying a chemical compound which specifically binds to a polypeptide of claim 10 which comprises separately contacting the polypeptide, with both the

chemical compound and a second chemical compound known to bind to the polypeptide, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the polypeptide, a decrease in the binding of the second chemical compound to the polypeptide in the presence of the chemical compound indicating that the chemical compound binds to the polypeptide.

10

79. The process of claim 78, wherein the specific binding of the compound to the polypeptide is detected by means of an antibody which binds to the polypeptide.

15

80. The process of claim 78, wherein the specific binding of the compound to the polypeptide is detected by a scintillation proximity assay.

20

81. The process of claim 78, wherein the polypeptide has substantially the same amino acid sequence as that shown in Figure 5.

25

82. The process of claim 78, wherein the compound is not previously known to bind to the polypeptide.

83. A compound determined by the process of claim 78.

30

84. A pharmaceutical composition which comprises an effective amount of a compound determined by the process of claim 78 and a pharmaceutically acceptable carrier.

35

85. A process for identifying a chemical compound which specifically binds to a polypeptide encoded by a nucleic acid of claim 8 or 9, which comprises contacting cells containing DNA encoding and

expressing on the cell surface the polypeptide, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the polypeptide.

5

86. The process of claim 85, wherein the polypeptide has substantially the same amino acid sequence as that shown in Figure 5.

10

87. The process of claim 85, wherein the compound is not previously known to bind to the polypeptide.

88. A compound determined by the process of claim 85.

15

89. A pharmaceutical composition which comprises an effective amount of a compound determined by the process of claim 85 and a pharmaceutically acceptable carrier.

20

90. The process of claim 85, wherein the cell is an insect cell.

91. The process of claim 85, wherein the cell is a mammalian cell.

25

92. The process of claim 91, wherein the cell is nonneuronal in origin.

30

93. The process of claim 92, wherein the nonneuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell or an LM(tk-) cell.

35

94. A process for identifying a chemical compound which specifically binds to a polypeptide encoded by a nucleic acid of claim 8 or 9, which comprises contacting a membrane fraction from a cell extract of cells containing DNA encoding and expressing on

their cell surface the polypeptide, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the polypeptide.

5

95. The process of claim 94, wherein the polypeptide has substantially the same amino acid sequence as that shown in Figure 5.

10

96. The process of claim 94, wherein the compound is not previously known to bind to the polypeptide.

97. A compound determined by the process of claim 94.

15

98. A pharmaceutical composition which comprises an effective amount of a compound determined by the process of claim 94 and a pharmaceutically acceptable carrier.

20

99. The process of claim 94, wherein the cell is an insect cell.

100. The process of claim 94, wherein the cell is a mammalian cell.

25

101. The process of claim 100, wherein the cell is nonneuronal in origin.

30

102. The process of 101, wherein the nonneuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell or an LM(tk-) cell.

35

103. A process involving competitive binding for identifying a chemical compound which specifically binds to a polypeptide encoded by a nucleic acid of claim 8 or 9, which comprises separately contacting cells expressing on their cell surface the

polypeptide, with both the chemical compound and a second chemical compound known to bind to the polypeptide, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the polypeptide, a decrease in the binding of the second chemical compound to the polypeptide in the presence of the chemical compound indicating that the chemical compound binds to the polypeptide.

104. The process of claim 103, wherein the polypeptide has the amino acid sequence shown in Figure 5 (Seq. I.D. No. 10).
105. The process of claim 103, wherein the cell is an insect cell.
106. The process of claim 103, wherein the cell is a mammalian cell.
107. The process of claim 106, wherein the cell is nonneuronal in origin.
108. The process of claim 107, wherein the nonneuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell or an LM(tk-) cell.
109. The process of claim 103, wherein the compound is not previously known to bind to the polypeptide.
110. A compound determined by the process of claim 103.
111. A pharmaceutical composition which comprises an effective amount of a compound determined by the process of claim 103 and a pharmaceutically acceptable carrier.

112. A process involving competitive binding for identifying a chemical compound which specifically binds to a polypeptide encoded by a nucleic acid of claim 8 or 9, which comprises separately contacting a membrane fraction from a cell extract of cells expressing on their cell surface the polypeptide, with both the chemical compound and a second chemical compound known to bind to the polypeptide, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the polypeptide, a decrease in the binding of the second chemical compound to the polypeptide in the presence of the chemical compound indicating that the chemical compound binds to the polypeptide.
113. The process of claim 112, wherein the polypeptide has the amino acid sequence shown in Figure 5 (Seq. I.D. No. 10).
114. The process of claim 112, wherein the cell is an insect cell.
115. The process of claim 112, wherein the cell is a mammalian cell.
116. The process of claim 115, wherein the cell is nonneuronal in origin.
117. The process of claim 116, wherein the nonneuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell or an LM(tk-) cell.
118. The process of claim 112, wherein the compound is not previously known to bind to the polypeptide.

119. A compound determined by the process of claim 112.

120. A pharmaceutical composition which comprises an effective amount of a compound determined by the process of claim 112 and a pharmaceutically acceptable carrier.

121. A method of screening a plurality of chemical compounds not known to bind to a polypeptide encoded by a nucleic acid of claim 8 or 9 to identify a compound which specifically binds to the polypeptide, which comprises:

(a) contacting cells transfected with and expressing DNA encoding the polypeptide with a compound known to bind specifically to the polypeptide;

(b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically to the polypeptide, under conditions permitting binding of compounds known to bind the polypeptide;

(c) determining whether the binding of the compound known to bind to the polypeptide is reduced in the presence of the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so

(d) separately determining the binding to the polypeptide of each compound included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the polypeptide.

122. The method of claim 121, wherein the cell is a mammalian cell.
- 5 123. The method of claim 122, wherein the mammalian cell is non-neuronal in origin.
124. The method of claim 123 wherein the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an LM(tk-) cell or an NIH-3T3 cell.
- 10 125. A pharmaceutical composition comprising an effective amount of a compound identified by the method of claim 121 and a pharmaceutically acceptable carrier.
- 15 126. A method of screening a plurality of chemical compounds not known to bind to a polypeptide of claim 10 to identify a compound which specifically binds to the polypeptide, which comprises:
- 20 (a) preparing a cell extract or cell supernatant from cells transfected with and expressing DNA encoding the polypeptide and contacting the cell extract or cell supernatant with a compound known to bind specifically to the polypeptide;
- 25 (b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically to the polypeptide, under conditions permitting binding of compounds known to bind the polypeptide;
- 30 (c) determining whether the binding of the compound known to bind to the polypeptide is reduced in the presence of the compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so
- 35



(d) separately determining the binding to the polypeptide of each compound included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the polypeptide.

127. The method of claim 126, wherein the cell is a mammalian cell.

128. The method of claim 127, wherein the mammalian cell is non-neuronal in origin.

129. The method of claim 128 wherein the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an LM(tk-) cell or an NIH-3T3 cell.

130. A pharmaceutical composition comprising an effective amount of a compound identified by the method of claim 126 and a pharmaceutically acceptable carrier.

131. A process for determining whether a chemical compound is an Ob receptor agonist which comprises contacting cells transfected with and expressing DNA of claim 9 with the compound under conditions permitting the activation of the Ob receptor, and detecting an increase in Ob receptor activity, so as to thereby determine whether the compound is an Ob receptor agonist.

132. A process for determining whether a chemical compound is an Ob receptor agonist which comprises preparing a cell extract from cells transfected with and expressing DNA of claim 9, isolating a membrane fraction from the cell extract, contacting the membrane fraction with the compound under conditions permitting the activation of the Ob receptor, and

detecting an increase in Ob receptor activity, so as to thereby determine whether the compound is an Ob receptor agonist.

- 5      133. A process for determining whether a chemical compound is an Ob receptor antagonist which comprises contacting cells transfected with and expressing DNA of claim 9 with the compound in the presence of a known Ob receptor agonist, under  
10      conditions permitting the activation of an Ob receptor, and detecting a decrease in Ob receptor activity, so as to thereby determine whether the compound is an Ob receptor antagonist.
- 15      134. A process for determining whether a chemical compound is an Ob receptor antagonist which comprises preparing a cell extract from cells transfected with and expressing DNA of claim 9, isolating a membrane fraction from the cell extract,  
20      contacting the membrane fraction with the ligand in the presence of a known Ob receptor agonist, under conditions permitting the activation of the Ob receptor, and detecting a decrease in Ob receptor activity, so as to thereby determine whether the  
25      compound is an Ob receptor antagonist.
- 30      135. The process of any one of claims 131, 132, 133, or 134, wherein the Ob receptor is a mammalian Ob receptor.
- 35      136. The process of any one of claims 131, 132, 133, or 134, wherein the cell is an insect cell.
137. The process of any one of claims 131, 132, 133, or 134, wherein the cell is a mammalian cell.

138. The process of claim 137, wherein the cell is nonneuronal in origin.

5 139. The process of claim 138, wherein the nonneuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, an NIH-3T3 cell or an LM(tk-) cell.

10 140. A pharmaceutical composition comprising an effective amount of a polypeptide of claim 10 and a pharmaceutically acceptable carrier.

141. The pharmaceutical composition of claim 140, wherein the pharmaceutical composition is a liquid.

15 142. The pharmaceutical composition of claim 141, wherein the carrier is isotonic saline.

20 143. A method for determining whether a compound modulates leptin activity which comprises:

(a) administering to an animal a polypeptide of claim 10 and measuring the amount of food intake, metabolic, or body weight changes in the animal;

25 (b) administering to a second animal both the polypeptide and the compound, and measuring the amount of food intake, metabolic, or body weight changes in the second animal; and

30 (c) determining whether the amount of food intake, metabolic, or body weight change is altered in the presence of the compound relative to the amount of food intake, metabolic, or body weight change in the absence of the compound, so as to thereby determine whether the compound modulates leptin activity.

35

2025 RELEASE UNDER E.O. 14176

144. A method of screening a plurality of compounds to identify a compound which modulates leptin activity which comprises:

- 5           (a) administering to an animal a polypeptide of claim 10 and measuring the amount of food intake, metabolic, or body weight changes in the animal;
- 10           (b) administering to a second animal the polypeptide and at least one compound of the plurality of compounds and measuring the amount of food intake, metabolic, or body weight changes in the animal;
- 15           (c) determining whether the amount of food intake, metabolic, or body weight change is altered in the presence of at least one compound of the plurality relative to the amount of food intake, metabolic, or body weight change in the absence of at least one compound of the plurality, and if so;
- 20           (d) separately determining whether each compound modulates leptin activity according to the method of claim 143, so as to thereby identify a compound which modulates leptin activity.
- 25

145. A method of treating an abnormality in a subject, wherein the abnormality is alleviated by modulating the activity of leptin in the subject, which comprises administering to a subject an amount of the pharmaceutical composition of claim 140 effective to modulate the activity of leptin in the subject, thereby treating the abnormality in the subject.

30

35

146. The method of claim 145, wherein the pharmaceutical composition is administered with food.
- 5 147. The method of claim 145, wherein the subject is a vertebrate, a mammal, a human, a canine or a feline.
148. A method of claims 145, wherein the pharmaceutical composition comprises an injectable carrier.
- 10 149. The method of claim 145, wherein the pharmaceutical composition comprises a wild-type polypeptide.
- 15 150. A method of modulating feeding behavior or metabolism of a subject which comprises administering to the subject an amount of a polypeptide of claim 10 effective to modulate the feeding behavior or metabolism of the subject so as to thereby modulate feeding behavior or metabolism of the subject.
- 20 151. The method of claim 150, wherein the subject's anorexia is treated.
- 25 152. The method of claim 150, wherein the subject's weight loss associated with cancer is treated.
153. The method of claim 150, wherein the subject's reduced appetite associated with aging is treated.
- 30 154. The method of claim 150, wherein the subject's obesity is treated.
155. The method of claim 150, wherein the subject's bulimia is treated.
- 35 156. The method of claim 150, wherein the compound is administered with food.

157. The method of claim 150, wherein the subject is a vertebrate, a mammal, a human, a canine or a feline.
- 5 158. A method of claim 150, wherein the polypeptide is administered in a pharmaceutical composition comprising an injectable carrier.
159. The method of claim 150, wherein the polypeptide is a wild-type polypeptide.
- 10 160. A method of modulating feeding behavior or metabolism of a subject which comprises administering a polypeptide of claim 10 and a compound which binds to the Y5 receptor, the amount of such polypeptide and compound being effective to modulate the feeding behavior or metabolism of the subject.
- 15 161. The method of claim 160, wherein the polypeptide and the compound are administered in combination.
- 20 162. The method of claim 160, wherein the polypeptide and the compound are administered separately.
- 25 163. The method of claim 160, wherein the polypeptide and the compound are administered once.
164. The method of claim 160, wherein the polypeptide and the compound are administered alternately.
- 30 165. The method of claim 160, wherein the polypeptide and the compound are administered repeatedly.
166. The method of claim 160, wherein the polypeptide and compound are administered with food.
- 35 167. The method of claim 160, wherein the subject is a

vertebrate, a mammal, a human, a canine or a feline.

168. A method of claim 160, wherein the polypeptide and compound are administered in a pharmaceutical composition comprising an injectable carrier.
169. The method of claim 160, wherein the polypeptide is a wild-type polypeptide.
170. A method of modulating feeding behavior or metabolism in a subject which comprises administering to the subject an amount of a compound which binds to a polypeptide of claim 10 effective to alter the activity of leptin in the subject, so as to thereby modulate feeding behavior or metabolism of the subject.
171. The method of claim 170, wherein the subject's anorexia is treated.
172. The method of claim 170, wherein the subject's weight loss associated with cancer is treated.
173. The method of claim 170, wherein subject's reduced appetite associated with aging is treated.
174. The method of claim 170, wherein the subject's obesity is treated.
175. The method of claim 170, wherein the subject's bulimia is treated.
176. The method of claim 170, wherein the compound is administered with food.
177. The method of claim 170, wherein the subject is a vertebrate, a mammal, a human, a canine or a feline.

0311676-071693

178. A method of claim 170, wherein the compound is administered in a pharmaceutical composition comprising an injectable carrier.
- 5 179. The method of claim 170, wherein the polypeptide is a wild-type polypeptide.
- 10 180. A method of modulating feeding behavior or metabolism of a subject which comprises administering a compound which binds to a polypeptide of claim 10 and a second compound which binds to the Y5 receptor, the amount of the first compound and the second compound being effective to modulate the feeding behavior or metabolism of the subject.
- 15 181. The method of claim 180, wherein the compound and the second compound are administered in combination.
- 20 182. The method of claim 180, wherein the compound and the second compound are administered separately.
183. The method of claim 180, wherein the compound and the second compound are administered once.
- 25 184. The method of claim 180, wherein the compound and the second compound are administered alternately.
- 30 185. The method of claim 180, wherein the compound and the second compound are administered repeatedly.
186. The method of claim 180, wherein the compound and second compound are administered with food.
- 35 187. The method of claim 180, wherein the subject is a vertebrate, a mammal, a human, a canine or a feline.



188. A method of claim 180, wherein the compound and second compound are administered in a pharmaceutical composition comprising an injectable carrier.

189. The method of claim 180, wherein the polypeptide is a wild-type polypeptide.

190. A method of detecting expression of a polypeptide of claim 10 by detecting the presence of mRNA coding for the polypeptide which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with the nucleic acid probe of claim 49 under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of the polypeptide by the cell.

191. A method of detecting the presence of a polypeptide which comprises contacting the cell or cell supernatant with the antibody of claim 56 under conditions permitting binding of the antibody to the polypeptide, detecting the presence of the antibody bound to the cell or cell supernatant, and thereby detecting the presence of a polypeptide.

192. A method of determining the physiological effects of varying levels of activity of polypeptides which comprises producing a transgenic nonhuman mammal of claim 65 whose levels of polypeptide activity are varied by use of an inducible promoter which regulates polypeptide expression.

193. A method of determining the physiological effects of varying levels of activity of polypeptides which comprises producing a panel of transgenic nonhuman mammals of claim 65 each expressing a different

amount of polypeptide.

194. A method for diagnosing a predisposition to a disorder associated with the activity of a specific polypeptide allele which comprises:
- 5 (a) obtaining DNA of subjects suffering from the disorder;
  - 10 (b) performing a restriction digest of the DNA with a panel of restriction enzymes;
  - (c) electrophoretically separating the resulting DNA fragments on a sizing gel;
  - 15 (d) contacting the resulting gel with a nucleic acid probe capable of specifically hybridizing with a unique sequence included within the sequence of a nucleic acid molecule encoding a polypeptide and labeled with a detectable marker;
  - 20 (e) detecting labeled bands which have hybridized to the nucleic acid of claim 1 labeled with a detectable marker to create a unique band pattern specific to the DNA of subjects suffering from the disorder;
  - 25 (f) preparing DNA obtained for diagnosis by steps a-e; and
  - 30 (g) comparing the unique band pattern specific to the DNA of subjects suffering from the disorder from step e and the DNA obtained for diagnosis from step f to determine whether the patterns are the same or different and to diagnose thereby predisposition to the disorder if the
  - 35

patterns are the same.

- 5 195. The method of claim 194 wherein the disorder associated with the activity of a specific polypeptide allele is diagnosed.
196. A method of preparing the purified polypeptide of claim 10 which comprises:
- 10 (a) inducing cells to express the polypeptide;
- (b) recovering the polypeptide from the induced cells; and
- 15 (c) purifying the polypeptide so recovered.
197. The method of claim 196, wherein the cell is placed in a serum-free growth medium.
- 20 198. The method of claim 196, wherein the polypeptide is recovered by affinity chromatography.
199. The method of claim 196, wherein the affinity chromatography comprises the use of leptin.
- 25 200. The method of claim 196, wherein the polypeptide is recovered by means of antibody binding.
- 30 201. The method of claim 200, wherein the antibody is directed to a flag epitope modification of the wild-type polypeptide.
202. A method of preparing the purified polypeptide of claim 10 which comprises:
- 35 (a) inserting nucleic acid encoding the polypeptide in a suitable vector;

- (b) introducing the resulting vector in a suitable host cell;
- 5 (c) placing the resulting cell in suitable condition permitting the production of the isolated polypeptide;
- (d) recovering the polypeptide produced by the resulting cell; and
- 10 (e) purifying the polypeptide so recovered.
203. The method of claim 202, wherein the cell is placed in a serum-free growth medium.
- 15 204. The method of claim 202, wherein the polypeptide is recovered by affinity chromatography.
205. The method of claim 202, wherein the affinity chromatography comprises the use of leptin.
- 20 206. The method of claim 202, wherein the polypeptide is recovered by means of antibody binding.
- 25 207. The method of claim 206, wherein the antibody is directed to a flag epitope modification of the wild-type polypeptide.

## DNA ENCODING A HUMAN Ob RECEPTOR (Ob-Re) AND USES THEREOF

## ABSTRACT OF THE DISCLOSURE

5 This invention provides an isolated nucleic acid encoding a polypeptide, a purified polypeptide, vectors comprising isolated nucleic acid encoding a polypeptide, cells comprising such vectors, antibodies directed to a polypeptide, nucleic acid probes useful for detecting nucleic acid encoding a polypeptide, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a polypeptide, nonhuman transgenic animals which express DNA encoding a normal or a mutant polypeptide, methods of isolating a polypeptide, methods of treatment eating disorders as well as methods of  
10 determining binding of compounds to polypeptides.  
15

FIG. 1




FIG. 2A





FIG. 2B



# FIG. 3A

Sequence across the mouse intron-exon border:

aatggttaaaaaaggtttcacatccacggtatgtgtactgtactttttcatggatttag  
 N V K K F H I H G M C T V L F M D \*

Sequence across the human intron-exon border:

tctgtttaagaagtagtattatccatggtaagtttactatacttttag  
 S V K K Y Y I H G K F T I L \*

# FIG. 3B

Mouse Ob-Re: ggtatgtgtactgtactttttcatggat

Human Ob-Re: ggtaagtttactatactt

Mouse Ob-Re: G M C T V L F M D  
 Human Ob-Re: G K F T I L

FIG. 4A

1 ATGATTTGTCAAAAATTCGTGTGGTTTTGTGTACATTTGGGAATTTATTTATGTGATAACT 60  
61 GCGTTTAACTTTGTGCATATCCAATTTACTCTGTGGAGATTTAAAGTTGTCTTGTGATGCCACCA 120  
121 AATTC AACCTATGACTACTTCCCTTTTGGCTGCTGGACTTCAAAAGAACTACTTCAAATTCG 180  
181 AATGGACATTAAGACAGCTGTTGAACCTAAGTTTAAATTCAGATGGTACTCACTTTTCT 240  
241 AACTTATCCAAAACAACTTTCACCTGTTCCTTCGGAGTGAGCAAGATAGAAAACGTGCTCC 300  
301 TTATGTGCAGACAACATTTGAAGGAAAAGACATTTGTTTCAACAGTAAATCTTTAGTTTPT 360  
361 CAAACAAATAGATGCAAACTGGAACATACAGTGCCTGGCTAAAAGGAGACTTAAAAATATTTC 420  
421 ATCTGTTATGTGGAGTCAATTAATTAAGAACTATTTACAGGAATTAATACTATAAGGTCCAT 480  
481 CTTTTATATGTTCTGCTGAAGTGTAGAGATTCACCTCTGGTTCCCCAAAAAGGCAGT 540  
541 TTTTCAGATGGTTCACCTGCAATTCAGTGTTCATGAATGTTGTGAATGTCTTGTGCTGTG 600  
601 CCAACAGCCAACTCAACGACACTCTCCTTATGTGTGTTTGAATAATCACATCTGGTGGAGTA 660  
661 ATTTTCCAGTCACTCTTAATGTGCTAGTTCAGCCCAATAATATGGTGAAGCTGATCCACCA 720  
721 TTAGGTTTGCATATGGAATAACACAGATGATGGTAAATTTAAAGATTTCTTGGTCCAGCCCA 780  
781 CCAATTGGTACCAATTTCCACTTCAATATCAAGTGAAATATTCAGAGAAATTTACACAGTT 840  
841 ATCAGAGAAGCTGACAAAGATGTCTCAGTACATCCCTGCTAGTAGACAGTATACTTCTCT 900  
901 GGGTCTTCGTATGAGGTTTCAGGTGAGGGCAAGAGACTGGATGGCCCGAGGAATCTGGAGT 960  
961 GACTGGAGTACTCCTCGTGTCTTTTACCACACAAGATGTGCATATACTTTCCACCTAAAAAT 1020  
1021 CTGACAAGTGTGGGTCTAAATGTTTCTTTTTCACCTGCATCTATAAGAAAGGAAACAGAT 1080  
1081 GTTCCCTCAAAAGAGATGTTTGGTGGATGAAATTAGCTGAGAAAATTTCTCAAAGCCAG 1140  
1141 TATGATGTTGTGAGTGCATGTTAGCAAAGTTACTTTTTTCAATCTGAAATGAAACCAAA 1200  
1201 CCTCGAGGAAAGTTTACCTATGATGCAGTGTACTGCTGCAATGAAACATGAATGCCATCAT 1260



FIG. 4B

1261	CGCTATGCTGAATTATATGTGATGTCAATATCAATATCTCATGTGAAACTGATGGG	1320
1321	TACTTTAACTAAATGACTTGCAGATGGTCAACCAGTCAATCCAGTCACTTGGGAAAGC	1380
1381	ACTTTGCAATTCGAGGTATCATAGGAGCAGCCTTTACTGTTCTGATATTCCTATCTATTCAT	1440
1441	CCCATACTGAGCCCCAAAGATTGGCTATTTGCAGAGTGAATGGTTTTTATGAAATGCATTTTC	1500
1501	CAGCCAATCTTCCCTATTATCTGGCTACACAAATGTGGATTAGGATCAATCACCTCTCTAGGT	1560
1561	TCACTTGACTCTCCACCAACATGTGCTCTCCTGATTCTGTGGTGAAGCCACTGCTCCA	1620
1621	TCCAGTGTGAAAGCAGAAAATTACTATAAAACATTGGATTATTTGAAAATATCTTTGGGAAAAG	1680
1681	CCAGTCTTTCCAGAGAAATAACCTTCAATCCAGATTCCGCTATGGTTTAAAGTGGAAAAGAA	1740
1741	GTACAAATGGAAGATGTATGAGGTTTATGATGCAAAATCAAAATCTGTCAGTCTCCCAGTT	1800
1801	CCAGACTTGTGTCAGTCTATGCTGTTCAAGGTGCGCTGTAAGAGGCTAGATGGACTGGGA	1860
1861	TATTTGGAGTAATTTGGAGCAATCCAGCCTACACAGTTGTCATGGGATATAAAAGTTCCCTATG	1920
1921	AGAGGACCTGAAATTTTGGAGAAATAATTAATGGAGATACATGAAAAAGGAGAAAAATGTC	1980
1981	ACTTTACTTTTGGAAAGCCCTGATGAAAAATGACTCAATTTGTCAGTGTTCAGAGATATGTG	2040
2041	ATAAACCATCATACTTCTCTGCAATGGAACATGCTCAGAAAGATGTGGGAAATCACACAGAA	2100
2101	TTCACTTTCTCTGGACAGAGCAAGCATACATCTGTTACGGTTCTGGCCATCAATTCAAAT	2160
2161	GGTGCTTCTGTGCAAAATTTTAAATTTAACTTTTCAATGGCCTATGAGCAAAAGTAAATATC	2220
2221	GTGCAGTCACTCAGTGTATCTCTTTAAACAGCAGTTTGTGTGATTGTTTCTCGGATACTA	2280
2281	TCACCCAGTGAATTACAAGCTAATGTATTTTATTATTTAGTGGAAAAATCTTAATGAAGAT	2340
2341	GGTGAATAAATGGCTTAGAATCTCTTCATCTGTTAAGAAATATTATATCCATGGTAAAG	2400
2401	TTTACTATACITTTAG	2415

FIG. 5A

1	M	I	C	Q	K	F	C	V	V	L	H	W	E	F	I	Y	C	V	T	20
21	A	F	N	L	S	Y	P	I	T	P	R	F	K	S	S	M	T	M	P	40
41	N	Y	T	Y	T	Y	N	L	L	A	G	L	S	S	N	C	R	N	P	60
61	N	E	T	K	I	T	N	V	E	K	F	N	E	S	H	C	T	V	S	80
81	N	T	A	D	N	I	A	K	C	S	R	S	T	S	N	S	R	L	S	100
101	L	C	I	D	N	E	W	F	L	V	V	S	K	Q	D	S	L	V	F	120
121	Q	Q	Y	V	S	N	L	C	F	C	W	S	T	V	N	S	Y	L	F	140
141	I	C	Y	V	P	N	L	F	C	L	F	R	K	G	D	L	K	V	H	160
161	L	L	Y	V	H	S	E	V	D	H	S	P	L	V	N	Q	K	G	S	180
181	F	L	M	V	L	C	N	T	M	E	E	P	C	V	P	L	V	P	V	200
201	P	T	A	K	L	P	N	S	T	P	C	L	E	I	G	S	G	P	V	220
221	I	F	Q	S	P	M	N	V	D	R	I	N	K	V	T	P	W	D	P	240
241	L	G	H	H	F	F	I	L	Q	V	K	L	S	I	S	S	S	S	P	260
261	P	L	P	A	D	E	L	A	Y	S	R	L	E	V	N	S	I	T	V	280
281	I	R	E	Y	E	P	V	T	G	R	L	L	D	G	D	S	I	L	P	300
301	G	S	S	T	P	R	V	F	A	K	V	V	I	P	S	G	I	W	S	320
321	D	W	S	V	G	S	N	T	C	R	D	L	I	F	P	P	K	I	I	340
341	L	T	S	S	I	S	V	S	H	N	L	A	E	K	Q	E	N	S	Q	360
361	V	P	S	V	D	I	V	W	M	N	T	F	F	K	K	P	P	K	K	380
381	Y	D	V	V	H	V	V	S	K	V	C	A	N	N	E	E	C	T	H	400
401	P	R	G	K	T	D	A	A	V	Y	C	F	N	E	C					420

FIG. 5B

421 R Y L L I P L S S V Q D L W G L N T F A S Q P S E I I F  
 441 Y T T P Q S S P V Q D L W G L N T F A S Q P S E I I F  
 461 T P Q S S P V Q D L W G L N T F A S Q P S E I I F  
 481 P Q S S P V Q D L W G L N T F A S Q P S E I I F  
 501 Q S S P V Q D L W G L N T F A S Q P S E I I F  
 521 S S P V Q D L W G L N T F A S Q P S E I I F  
 541 S S P V Q D L W G L N T F A S Q P S E I I F  
 561 P V Q D L W G L N T F A S Q P S E I I F  
 581 V Q D L W G L N T F A S Q P S E I I F  
 601 Q D L W G L N T F A S Q P S E I I F  
 621 D L W G L N T F A S Q P S E I I F  
 641 L W G L N T F A S Q P S E I I F  
 661 W G L N T F A S Q P S E I I F  
 681 G L N T F A S Q P S E I I F  
 701 L N T F A S Q P S E I I F  
 721 N T F A S Q P S E I I F  
 741 T F A S Q P S E I I F  
 761 F A S Q P S E I I F  
 781 A S Q P S E I I F  
 801 S Q P S E I I F

FIG. 6A



FIG. 6B




FIG. 7A





FIG. 7B



9/14

FIG. 7C






FIG. 7D



10/14








FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 11A






FIG. 11B



# United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division



## Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
  - ☐ All sheets must be the same size and either A4 (21 cm x 29.7 cm) or 8-1/2" x 11". Pages \_\_\_\_\_ do not meet these requirements.
  - ☐ Papers are not flexible, strong, smooth, non-shiny, durable, and white.
  - ☐ Papers are not typewritten or mechanically printed in permanent ink on one side.
  - ☐ Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
  - ☐ Papers contain hand lettering.
2. Drawings are not in compliance and were not scanned because:
  - ☐ The drawings or copy of drawings are not suitable for electronic reproduction.
  - ☐ All drawings sheets are not the same size. Pages must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
  - ☐ Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").
3. Page(s) \_\_\_\_\_ are not of sufficient clarity, contrast and quality for electronic reproduction.
4. Page(s) \_\_\_\_\_ are missing.
5. OTHER: NO Declaration

09116676.071698